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Rationale. ±3, 4-methelynedioxymethamphetamine (MDMA) is the primary 
psychoactive ingredient of the increasingly popular recreational street drug, ecstasy. As 
with other drugs of abuse, repeated intermitted exposure to MDMA can lead to an increase 
in the subsequent behavioural effects of the drug. This phenomenon, termed behavioural 
sensitisation, has been attributed to sensitisation of central DAergic mechanisms 
considered to underlie several aspects of addiction.  
Objectives. The purpose of the present research was to investigate the role of DA 
D2 receptor mechanisms in the development of MDMA sensitisation and the acquisition of 
MDMA self-administration in rats.  
Methods. Rats received daily i.p. injections of the selective D2 antagonist, 
eticlopride (0.0, 0.05, 0.3 mg/kg), prior to injections of MDMA (0.0, 10.0 mg/kg) for five 
days. Two days following the final pre-treatment session, the locomotor activating effects 
of MDMA (5 mg/kg, i.p.) were determined. Another group of rats were surgically 
implanted with i.v. jugular catheters before undergoing the same pre-treatment regimen.  
Two days following the final pre-treatment session, these rats were subsequently tested for 
acquisition of MDMA self-administration. The locomotor activating effects of MDMA (5 
mg/kg i.p.) were determined two days following the last self-administration session.  
Results. Pre-treatment with MDMA enhanced the locomotor activating effects of 
MDMA and facilitated the acquisition of MDMA self-administration, as evidenced by an 
increased likelihood to meet an acquisition criterion. Co-administration of eticlopride 
during pre-treatment completely blocked the development of sensitisation to MDMA-
produced hyperactivity but failed to significantly attenuate the facilitation of MDMA self-
administration. Interestingly, pre-treatment with eticlopride alone also facilitated the 
acquisition of self-administration. MDMA self-administration failed to alter MDMA-
produced locomotor hyperactivity.  
Conclusions. These findings suggest that repeated activation of DA D2 receptors is 
required for the development of sensitisation to MDMA-produced hyperactivity but not for 
the development of sensitisation to MDMA-produced reinforcement. D2 receptor 
mechanisms evidently play some role, however, because repeated exposure to eticlopride 
also facilitated MDMA self-administration. It is suggested that both sensitised DAergic 
mechanisms and desensitised 5-HTergic mechanisms contribute to the acquisition of 
MDMA self-administration.  




History of MDMA 
In 1912, the German pharmaceutical company, Merck, was interested in finding an 
alternate means of producing the antihemorrhagic drug, hydrastinine. Merck chemist, 
Atnon Köllisch, first synthesised ±3, 4-methelynedioxymethamphetamine (MDMA) as one 
of the intermediate compounds required to produce a methylated analogue of hydrastinine,  
methylhydrastinine (Bernschneider-Reif, Öxler, & Freudenmann, 2006; Freudenmann, 
Oxler, & Bernschneider-Reif, 2006). On December 24th, 1912, Merck applied for the 
procedural patents of methylhydrastinine and the precursor compounds involved in its 
synthesis, including MDMA (Merck, 1912a, 1912b) Over the next 5 decades, Merck 
records indicate MDMA was investigated sporadically, however, details of this research is 
scant (Bernschneider-Reif et al., 2006; Freudenmann et al., 2006).  
The first detailed research on MDMA was a toxicology study commissioned by the 
United States army in 1953 (Hardman, Haavik, & Seevers, 1973). Two decades later, the 
first report investigating the effects of MDMA in humans was published by Shulgin & 
Nichols (1978). They described the drug as inducing “an easily controlled altered state of 
consciousness with emotional and sensual overtones” (Shulgin & Nichols, 1978, p. 77). As 
promoted by Shulgin, MDMA began to be used as an adjunct to psychotherapy throughout 
the US (Beck, 1990; Shulgin, 2012). However, a dramatic increase in recreational use 
during the early 1980’s prompted the Drug Enforcement Administration to propose for the 
scheduling of MDMA which was later granted in 1985 (Beck, 1990; Lawn, 1985). In 
1987, New Zealand followed suit and scheduled MDMA as a Class B1 substance 
(Ministry of Health, 1975). In the United Kingdom, MDMA was already classified as a 
Class A drug since 1977 (Parliament of the United Kingdom, 1971).  
Despite its criminalisation in most countries, recreational use of MDMA continued 
to rise. MDMA was primarily being used by young people at festivals, parties, and dance 
clubs (Johnston, 2010; McDowell & Kleber, 1994). Throughout the 1980’s and 1990’s, the 
increasing popularity of the rave subculture led to widespread use of MDMA, with it being 
one of the most commonly used illicit drugs at dance parties (Brown, Jarvie, & Simpson, 
1995; Engels & ter Bogt, 2004; Lenton, Boys, & Norcross, 1997; Parks & Kennedy, 2004; 
Weir, 2000; Wilkins, Bhatta, Pledger, & Casswell, 2003). Today, use of MDMA has 
spread to mainstream populations, as consumption patterns and contexts of use have 
become more variable (Degenhardt, Barker, & Topp, 2004; Hansen, Maycock, & Lower, 
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2001; von Sydow, Lieb, Pfister, Höfler, & Wittchen, 2002; Wilkins, Prasad, Wong, & 
Rychert, 2014).  
It should be noted that MDMA is typically consumed in pills or tablets often 
containing a number of other compounds (Parrott, 2004). For example, recent testing of 
pills seized by the New Zealand police revealed traces of benzylpiperazine (BZP), 
trifluoromethylphenylpiperazine (TFMPP), methylmethcathinone (mephedrone), 
methylethcathinone (4‐MEC), dimethylamylamine (DMAA), 
methylenedioxymethcathinone (methylone), and caffeine (as cited in Wilkins, Jawalkar, 
Moewaka Barnes, Parker, & Asiasiga, 2014). Thus when outside of a controlled laboratory 
setting, MDMA will be referred to by the street name of these pills: ecstasy (also known as 
E, eccy, XTC, Molly, Adam, disco biscuits, among a number of other names). 
Prevalence of ecstasy 
It is estimated that there are ~19 million current ecstasy users worldwide (United 
Nations Office on Drugs and Crime [UNODC], 2015). For comparison, there are 
approximately ~17 million cocaine users and ~182 million cannabis users (UNODC, 
2015). In New Zealand and Australia, the annual prevalence of ecstasy use is particularly 
high, being among the highest in the world at 2.6% and 2.49%, respectively (Australian 
Institute of Health and Welfare, 2013; Ministry of Health, 2010; UNODC, 2015). For New 
Zealand, this is a 0.7% increase since 2003, where ecstasy continues to be the second most 
commonly used illicit drug after marijuana (Ministry of Health, 2003).  
European countries, particularly the Netherlands and Belgium, are the largest 
producers of ecstasy (UNODC, 2015). This is reflected by the average price of an ecstasy 
tablet in Europe ranging from as low as 3.10€ in Poland to 12.54€ in the UK (Winstock, 
2015). In New Zealand, the average price of an ecstasy tablet is the highest in the world at 
25.15 € (Winstock, 2015). This price has been steadily declining, however (Wilkins, 
Prasad, et al., 2014), which might be related to the increased production of ecstasy tablets 
in south-east Asia (UNODC, 2015). 
Effects of MDMA in humans 
Ecstasy has been rated as the most pleasurable recreational drug (Winstock, 2015). 
The most commonly reported subjective effect of MDMA is an increased sense of 
‘closeness’ with others (Peroutka, Newman, & Harris, 1988). Other subjective effects 
include increased sensory awareness, euphoria, enhanced insight, increased extraversion, 
elevated self-confidence, and modest sensory hallucinations (Downing, 1986; Liechti, 
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Gamma, & Vollenweider, 2001; Peroutka et al., 1988; Tancer & Johanson, 2003; 
Vollenweider, Gamma, Liechti, & Huber, 1998). The amphetamine-like physiological 
effects of MDMA include tachycardia, increased blood pressure, increased muscle tension, 
bruxism (teeth grinding), and dry mouth (Downing, 1986; Liechti et al., 2001; Peroutka et 
al., 1988; Tancer & Johanson, 2003; Vollenweider et al., 1998). Nausea and vomiting are 
occasionally reported side effects (Downing, 1986). MDMA also causes a significant 
increase in body temperature (Freedman, Johanson, & Tancer, 2005; Tancer & Johanson, 
2003; Torre et al., 2006). Negative side effects are common on the day following MDMA 
use. These include muscle aches, fatigue, paranoia, restlessness, supressed appetite, 
delirium, depression, anxiety, and difficulty concentrating (Parrott & Lasky, 1998; 
Peroutka et al., 1988; Vollenweider et al., 1998). Indeed many ecstasy users take other 
drugs to relieve such effects (Boys, Marsden, & Strang, 2001; Topp, Hando, Dillon, 
Roche, & Solowij, 1999; Winstock, Griffiths, & Stewart, 2001). 
Drug abuse/dependence 
Harmful drug use poses a significant threat to the health and wellbeing of society. 
Tobacco, alcohol, and illicit drug use was estimated to account for 10.29% of years of life 
lost due to disability or premature death in 2010, making it a top contributor to the global 
burden of disease (Degenhardt et al., 2013; Lim et al., 2012). The economic ramifications 
of this are severe. For example, the crime, healthcare, road crashes, and loss of 
productivity associated with harmful use of alcohol and other drugs (excluding tobacco) 
cost New Zealand approximately $6.5 billion in the year 2006, which is equivalent to the 
Global Domestic Product (GDP) of New Zealand’s agricultural ($6.7 billion) and finance 
industries ($7 billion; Slack, Nana, Webster, Stokes, & Wu, 2009).  
The previous Diagnostic and Statistical manual of Mental disorders (DSM-IV-TR) 
describes drug abuse as a maladaptive pattern of substance use leading to impairments in 
meeting work, school, or home obligations, with recurring legal, social, or interpersonal 
problems (American Psychiatric Association [APA], 2000). Drug dependence is more 
severe, being characterised by a much larger intake of the substance over longer periods of 
time than was intended, unsuccessful efforts to control use, tolerance and/or withdrawal, 
and continued use despite knowledge of recurring psychological, social, and physical 
problems caused by the drug (APA, 2000).  
The most recent DSM-5 combines drug abuse and dependence into a single 
disorder, substance use disorder, which is manifested by meeting at least 2 of the criteria 
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displayed in Table 1. Substance use disorder is sub classified by substance type and is 
measured along a continuum from mild (2 – 3 criteria) to severe (6+ criteria; APA, 2013). 
 
Table 1. 
DSM-5 substance use disorder criteria 
1. Taking the substance in larger amounts or for longer than you meant to. 
2. Wanting to cut down or stop using the substance but not managing to. 
3. Spending a lot of time getting, using, or recovering from use of the substance. 
4. Cravings and urges to use the substance. 
5. Not managing to do what you should at work, home, or school because of 
substance use. 
6. Continuing to use, even when it causes problems in relationships. 
7. Giving up important social, occupational, or recreational activities because of 
substance use. 
8. Using substances again and again, even when it puts you in danger. 
9. Continuing to use, even when you know you have a physical or psychological 
problem that could have been caused or made worse by the substance. 
10. Needing more of the substance to get the effect you want (tolerance). 
11. Development of withdrawal symptoms, which can be relieved by taking more of 
the substance. 
Source: American Psychiatric Association (2013). 
 
Ecstasy abuse/dependence 
Early findings indicated that ecstasy use was generally self-limited, being used 
once a week in heavier users on average (Beck & Rosenbaum, 1994; Hammersley, 1999; 
Solowij, Hall, & Lee, 1992). Tolerance to the positive effects of the drug and an increase 
of the negative after effects were the main reasons for cessation of use (Solowij et al., 
1992). These findings seemed to confirm the prevailing view at the time that ecstasy 
lacked the compulsive usage patterns typical of a drug of abuse/dependence (Downing, 
1986; Nichols & Glennon, 1984).  
However, more recent studies revealed a change in the self-limiting, occasional 
nature of ecstasy use. The number of ecstasy pills taken per session had escalated and use 
had become more frequent (Parrott, 2001; Pope Jr, Ionescu-Pioggia, & Pope, 2001). 
Ecstasy was being used at home or at friends’ houses, not just at dance parties (Degenhardt 
et al., 2004; Hansen et al., 2001; Strote, Lee, & Wechsler, 2002; Topp, Hall, & Hando, 
1997; Topp et al., 1999). Additionally, an increasing number of users reported injecting 
ecstasy (Topp et al., 1997, 1999). Tolerance to the positive subjective effects of ecstasy 
was being overcome by repeatedly self-administering the drug at increasing doses. For 
example, from a sample of 185 current ecstasy users, 83% of users reported significant 
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tolerance to the effects of the drug with 56% reporting that they had doubled the amount of 
ecstasy they take in a sitting in order to achieve similar effects compared to when they first 
started (Topp et al., 1997). While the positive effects of ecstasy decrease with repeated 
use, the amphetamine-like physiological effects can increase (Jansen, 1997; Peroutka, 
1990), which has led to some users developing a severe amphetamine-like dependence 
(Jansen, 1999).  
Several studies have documented an abuse/dependence syndrome among ecstasy 
users, based on DSM-IV criteria. Topp, Hall, and Hando (1997) found that 48% of their 
Australian sample of 185 current ecstasy users met DSM-IV criteria for drug dependence. 
They compared ecstasy use to binge drinking alcohol, as the majority of users did not use 
ecstasy on most days but still presented significant levels of ecstasy-related harm (Topp et 
al., 1997). In the US, 43% of ecstasy users met DSM-IV criteria for dependence and 34% 
meet the criteria for abuse (Cottler, Womack, Compton, & Ben-Abdallah, 2001). In a 
community survey of 3021 adolescents in Germany, 4% of males and 2.3% of females 
reported using ecstasy at least once; of these individuals, 20% met the DSM-IV criteria for 
abuse/dependence (P. Schuster, Lieb, Lamertz, & Wittchen, 1998). Yen and Hsu (2007) 
interviewed a sample of 200 adolescent Taiwanese ecstasy users and found that 22% meet 
adopted DSM-IV criteria for dependence. Finally, in a cross-national study, 15% and 59% 
of ecstasy users met DSM-IV criteria for abuse and dependence, respectively (Cottler, 
Leung, & Abdallah, 2009). The most prevalent dependence criteria were ‘continued use 
despite knowledge of physical/psychological problems’ and ‘withdrawal’ whereas the 
most prevalent abuse criteria were ‘physically hazardous use’ followed by ‘use despite 
knowledge of social problems’ (Cottler et al., 2009). 
Some ecstasy users have reported symptoms that are used to define a substance use 
disorder in the more recent DSM-V. For example, some users reported (1) taking ecstasy 
in larger amounts or for longer than they meant to (Cottler et al., 2001); (2) wanting to cut 
down or stop using ecstasy but not managing to (Topp et al., 1997); (3) cravings and urges 
to use ecstasy (Hopper et al., 2006); (4) continuing to use, even when they knew they had a 
physical or psychological problem that could have been caused or made worse by ecstasy 
(Cottler et al., 2009; Yen & Hsu, 2007); (5) tolerance to the positive effects (Parrott, 2005; 
Peroutka et al., 1988); and (6) development of withdrawal symptoms (Cottler et al., 2001; 
McKetin et al., 2014). 
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It should be noted that polydrug use is particularly prevalent among ecstasy users, 
which complicates the interpretation of clinical data (Topp et al., 1999). For example, 
current ecstasy users aged 14 – 19 years had used cannabis (88.3%), amphetamine 
(70.1%), LSD (27.1%), or cocaine (22.4%) within the past year (Degenhardt et al., 2004). 
Other drugs are often taken concurrently with ecstasy, usually in attempt to enhance the 
positive effects of the drug or to reduce the comedown effects  (Boys et al., 2001; Topp et 
al., 1999; Winstock et al., 2001).  
Ecstasy abuse has been attributed to the onset of several psychopathologies 
including paranoid psychosis, mixed affective psychosis, hallucinations, panic attacks, 
depression, and anxiety (Cassidy & Ballard, 1994; McGuire, Cope, & Fahy, 1994; Parrott, 
Sisk, & Turner, 2000; Series, Boeles, Dorkins, & Peveler, 1994; Topp et al., 1999; 
Williamson, 1997). Even when controlling for polydrug use, Yen and Hsu (2007) found 
that ecstasy use increased the risk for developing severe psychopathology. Ecstasy use has 
also been associated with cognitive deficits in memory and decision making (Halpern et 
al., 2004; Parrott, Lees, Garnham, Jones, & Wesnes, 1998; Roiser, Rogers, Cook, & 
Sahakian, 2006).  
Ecstasy/MDMA-induced hyperthermia, renal failure, hepatic toxicity, 
rhabdomyolysis, cardiac arrhythmia, and disseminated intravascular coagulation have 
contributed to a number of deaths (Chadwick, Curry, Linsley, Freemont, & Doran, 1991; 
Dykhuizen, Brunt, Atkinson, Simpson, & Smith, 1995; Fineschi & Masti, 1996; Freedman 
et al., 2005; Garcı́a-Repetto et al., 2003; Khakoo, Coles, Armstrong, & Barry, 1995; 
Schifano et al., 2003; Screaton et al., 1992). Alarmingly, emergency medical treatment of 
ecstasy users across the globe has increased from 0.3% of users in 2013 to 0.9% of users in 
2015 (UNODC, 2015). For comparison, 0.6% of cocaine users, 1.0% of marijuana users, 
and 1.2% of alcohol users required emergency medical treatment in 2015 (United Nations 
Office on Drugs and Crime [UNODC], 2015). With ecstasy/MDMA use being associated 
with reports of significant psychological morbidity and relatively high rates of 
dependence, coupled with the increasing number of users seeking emergency medical 
treatment, there is a need for a better scientific understanding of the drug and its effects. 
Self-administration 
Drug abuse research using human participants is limited by ethical considerations 
and the inability to control for several confounding variables such as polydrug use, drug 
purity, personal history, etc. (Carter & Griffiths, 2009; Schenk, 2009). Although drug 
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abuse is a human problem, the development of animal paradigms such as self-
administration (Shaham, Shalev, Lu, De Wit, & Stewart, 2003), conditioned place 
preference (Tzschentke, 2007), and drug discrimination (Overton, 1987) allows for the 
control of several variables that limit human research. Animal models have provided 
valuable insight into the neurochemical and behavioural mechanisms underlying drug 
taking. 
Since the development of the indwelling intravenous (i.v.) catheter (Weeks, 1962), 
reliable i.v. self-administration has been demonstrated in non-human primates (Deneau, 
Yanagita, & Seevers, 1969; Gerber & Stretch, 1975; Goldberg, Woods, & Schuster, 1971; 
Lamb & Griffiths, 1990; T. Thompson & Schuster, 1964), dogs (Risner & Jones, 1975), 
cats (Balster, Kilbey, & Ellinwood, 1976), rats (Collins, Weeks, Cooper, Good, & Russell, 
1983; Weeks & Collins, 1964), and mice (Criswell, 1983). Self-administration has proved 
to be an excellent method for evaluating the abuse liability of drugs. Drugs that are abused 
by humans are readily self-administered by laboratory animals, whereas drugs that are not 
abused by humans generally do not maintain self-administration in laboratory animals 
(Deneau et al., 1969; O’Connor, Chapman, Butler, & Mead, 2011; C. R. Schuster & 
Thompson, 1969). Indeed, the pre-clinical screening of potentially new pharmaceutical 
drugs involves evaluating their abuse liability using the self-administration paradigm (Ator 
& Griffiths, 2003; Food and Drug Administration, 2010) 
The standard self-administration paradigm involves a simple choice procedure. The 
depression of one (active) lever results in an infusion of the drug while the depression of 
another (inactive) lever has no programmed consequence. Significant preference for the 
active lever indicates that the drug is reinforcing, as it is maintaining the operant response 
of lever pressing (e.g. Corrigall & Coen, 1989; Schenk, Colussi-Mas, Do, & Bird, 2012; 
Williamson, 1997). Reversal of the levers results in the corresponding reversal of lever 
pressing (Goeders & Smith, 1983; Pickens & Harris, 1968). Replacement of the drug with 
saline results in the extinction of lever pressing, which can subsequently be reinstated by 
the reintroduction of the drug (e.g. Gerber & Stretch, 1975; Grove & Schuster, 1974; 
Pickens & Harris, 1968).  
The dose effect curve for self-administration typically takes the form of an inverted 
U. Low doses of drug often fail to reinforce responding, but above a threshold dose, the 
drug will reinforce high levels of responding. Laboratory animals will typically dose-
dependently alter their behavioural response in order to maintain a similar average daily 
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intake. That is, a lower infusion dose will result in more responses whereas a higher 
infusion dose will result in fewer responses (Goldberg, Hoffmeister, Schlichting, & 
Wuttke, 1971; Pickens & Harris, 1968; Weeks & Collins, 1964). Likewise, an increase in 
the fixed ratio (FR) will result in the proportional increase in the required behavioural 
response (Goldberg, Hoffmeister, et al., 1971; Pickens & Harris, 1968; Schenk et al., 
2012).  
MDMA self-administration 
Early studies involved substituting cocaine for MDMA in self-administration 
trained non-human primates. In rhesus monkeys, an inverted U shaped function for 
MDMA responding was produced and three of the four animals responded at rates above 
saline levels (Beardsley, Balster, & Harris, 1986). Two of these subjects responded at rates 
similar to cocaine while one subject did not self-administer MDMA at any of the doses 
tested (Beardsley et al., 1986). Subsequent studies showed that although MDMA 
maintained responding at levels higher than saline, rates of responding were generally less 
than cocaine and often highly variable (Fantegrossi et al., 2004; Fantegrossi, Ullrich, Rice, 
Woods, & Winger, 2002; Lamb & Griffiths, 1987; Lile, Ross, & Nader, 2005).  
Initial studies using naïve rats reported similar results. Responding for MDMA was 
generally low with an average of 3 – 4 responses per session and only 63% of animals 
maintained responding for MDMA at rates significantly greater than saline (Ratzenboeck, 
Saria, Kriechbaum, & Zernig, 2001). Other studies have found similar low rates of 
responding, that is, 2 – 7 responses per session (De La Garza, Fabrizio, & Gupta, 2007; 
Reveron, Maier, & Duvauchelle, 2006). This led to suggestions that MDMA was not a 
very efficacious reinforcer (Beardsley et al., 1986; Lamb & Griffiths, 1987; Ratzenboeck 
et al., 2001).  
Other studies have reported much higher levels of responding, however (Braida & 
Sala, 2002; Cornish et al., 2003; Dalley et al., 2007; Daniela, Brennan, Gittings, Hely, & 
Schenk, 2004; Schenk, Gittings, Johnstone, & Daniela, 2003). These mixed findings might 
be explained by differences in methodology. For example, in the study conducted by 
Ratzenbroeck and colleagues (2001), there were up to four sessions a day alternating with 
cocaine and saline self-administration. The lack of repeated discrete trials coupled with the 
relatively long half-life of MDMA may not have engendered optimal operant learning 
(Griffiths, Brady, & Bradford, 1979). Longer infusions times and shorter / lack of time out 
scheduling may also have contributed to higher rates of MDMA self-administration in 
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these studies (De La Garza et al., 2007). Nonetheless, a number of recent studies have 
reported reliable MDMA self-administration (Aarde, Miller, Creehan, Vandewater, & 
Taffe, 2015; Ball & Slane, 2012, 2014; Ball et al., 2015; Ball, Walsh, & Rebec, 2007; Bird 
& Schenk, 2013; Bradbury et al., 2013; Colussi-Mas, Wise, Howard, & Schenk, 2010; 
Creehan, Vandewater, & Taffe, 2015; Do & Schenk, 2013; Feduccia, Kongovi, & 
Duvauchelle, 2010; Gould et al., 2011; Kivell, Day, Bosch, Schenk, & Miller, 2010; 
Oakly, Brox, Schenk, & Ellenbroek, 2013; Reveron, Maier, & Duvauchelle, 2010; Schenk 
& Bradbury, 2015; Schenk et al., 2007; Z. Wang & Woolverton, 2007).  
Once acquired, MDMA self-administration is comparable to the self-administration 
of other drugs of abuse. MDMA self-administration produced an inverted U-shaped dose 
effect curve (Daniela et al., 2004; Ratzenboeck et al., 2001; Schenk et al., 2003). When the 
infusion dose was halved, the number of responses doubled in order to keep the intake of 
drug constant (Do & Schenk, 2013; Reveron et al., 2010; Schenk et al., 2012). Likewise, 
an increase the FR response requirement resulted in the proportional increase in lever 
pressing (Daniela, Gittings, & Schenk, 2006; Schenk, Gittings, & Colussi-Mas, 2011). 
Replacing MDMA with its vehicle solution resulted in extinction of the operant behaviour 
that was subsequently reinstated by reintroduction of the drug (Daniela et al., 2006; 
Schenk et al., 2011). Further, extinguished drug seeking behaviour following MDMA self-
administration was reinstated by priming injections of MDMA, cocaine, or yohimbine 
(stress inducer), and by the presentation of a light stimulus previously paired with MDMA 
infusions (Ball et al., 2015, 2007; Schenk et al., 2011; Schenk, Hely, Gittings, Lake, & 
Daniela, 2008).  
The acquisition of MDMA self-administration, however, exhibits a profile that 
differs from that of other drugs of abuse. Firstly, acquisition of MDMA self-administration 
proceeds with a protracted time course, with low rates of responding during initial test 
sessions (Schenk et al., 2012). Acquisition of MDMA self-administration typically 
requires around 15 daily sessions (Schenk et al., 2012) whereas cocaine or amphetamine 
self-administration is usually acquired within a few days (Carroll & Lac, 1997). A more 
striking difference is that only about 50% of rats meet acquisition criteria for MDMA self-
administration (Schenk et al., 2012) whereas virtually all animals acquire cocaine or 
amphetamine self-administration (Carroll & Lac, 1997). These differences may reflect the 
unique pharmacology of MDMA compared to other psychostimulant drugs of abuse.  
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Pharmacology of MDMA 
MDMA is a ring-substituted phenethylamine, being structurally similar to 
methamphetamine (psychostimulant) and mescaline (hallucinogen). It is a potent indirect 
agonist of the monoamine neurotransmitters: serotonin (5-HT), dopamine (DA), and 
noradrenaline (NA). This is accomplished by competitive binding to the monoamine 
transporters, which prevents the reuptake of monoamines increasing synaptic 
concentrations of 5-HT, DA, and NA (Battaglia, Brooks, Kulsakdinun, & De Souza, 1988; 
Berger, Gu, & Azmitia, 1992; Cleary & Docherty, 2003; Cole & Sumnall, 2003; J. L. 
Fitzgerald & Reid, 1990; Hekmatpanah & Peroutka, 1990; Hysek et al., 2011; Iravani, 
Asari, Patel, Wieczorek, & Kruk, 2000; Nash & Brodkin, 1991; Rudnick & Wall, 1992). 
Acting as a substrate for the monoamine transporters, MDMA also enters the neuron and 
interacts with the vesicular monoamine transporter 2 (VMAT-2), preventing the 
repackaging of cytosolic monoamines into vesicles whilst displacing monoamines from the 
vesicles into the cytosol (Bogen, Haug, Myhre, & Fonnum, 2003; Eiden & Weihe, 2011; J. 
L. Fitzgerald & Reid, 1990; Fleckenstein et al., 2002; Gu & Azmitia, 1993; Rudnick & 
Wall, 1992; Sabol & Seiden, 1998; Schuldiner, Steiner-Mordoch, Yelin, Wall, & Rudnick, 
1993; Sulzer & Rayport, 1990). Transporter reversal then results in the substantial efflux 
of cytosolic monoamines into the synapse (Crespi, Mennini, & Gobbi, 1997; Gudelsky & 
Nash, 2002; Rudnick & Wall, 1992). Because MDMA has an affinity for the 5-HT 
transporter several fold higher than the NA or the DA transporter, these effects are 
predominantly exerted on the 5-HT system (Battaglia, Brooks, et al., 1988).  
MDMA further potentiates its effects on the monoamine system by inhibiting 
monoamine oxidase (MAO), the enzyme that metabolises 5-HT, DA, and NA in the 
cytosol and extracellular space (Dworkin, Guerin, Co, Smith, & Goeders, 1988; Leonardi 
& Azmitia, 1994; Scorza et al., 1997). Moreover, MDMA may induce carrier-independent, 
Ca+ dependent, release of neurotransmitters via exocytosis (Crespi et al., 1997; 
Hondebrink, Meulenbelt, Meijer, van den Berg, & Westerink, 2011; Maura, Gemignani, 
Versace, Martire, & Raiteri, 1982; Nagayasu, Kitaichi, Shirakawa, Nakagawa, & Kaneko, 
2010). MDMA also induces the release of acetylcholine and has affinities for a range of 
brain receptors including the, 5-HT1 and 5-HT2 receptors, D1- and D2-like receptors, α1-, 
α2-, and β2-adrenergic receptors, as well as muscarinic and histamine receptors (Battaglia, 
Brooks, et al., 1988).  
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Measurement of synaptic concentrations of neurotransmitters using in vivo 
microdialysis has revealed that MDMA stimulates the release of 5-HT to a far greater 
extent than any other neurotransmitters (see Green, Mechan, Elliott, O’Shea, & Colado, 
2003; Gudelsky & Yamamoto, 2008). For example, Bauman and colleagues measured 
synaptic concentrations of 5-HT and DA in the nucleus accumbens (NAcc), caudate 
nucleus, and prefrontal cortex (PFC) following a range of MDMA doses in rats. The 
increase in synaptic 5-HT was 2 – 6 times greater than the increase in DA, depending on 
brain region and dose, although the lowest dose of MDMA (1 mg/kg) failed to 
significantly increase synaptic NAcc DA at all (Baumann, Clark, Franken, Rutter, & 
Rothman, 2008; Baumann, Clark, & Rothman, 2008; Baumann et al., 2005). The highest 
dose (7.5 mg/kg) increased 5-HT and DA concentrations in the NAcc by 3000% and 
500%, respectively (Baumann, Clark, Franken, et al., 2008). As will be discussed in the 
next section, this is not a pharmacological profile typical of drugs of abuse.  
Pharmacology of self-administration 
In all animals, including humans, natural rewards such as food or sex produce an 
increase in activity of the neurotransmitter, DA, particularly within the NAcc (Bassareo & 
Di Chiara, 1999a, 1999b; Fiorino, Coury, & Phillips, 1997; Pfaus, Mendelson, & Phillips, 
1990; Pfaus & Phillips, 1991; Schott et al., 2008; Schultz, Apicella, & Ljungberg, 1993). 
The NAcc receives DAergic input via the medial forebrain bundle from the ventral 
tegmental area (VTA; Oades & Halliday, 1987). The VTA is the origin of DA cell bodies 
that also project to the amygdala and PFC (Oades & Halliday, 1987). Drugs of abuse 
similarly act upon these DAergic pathways, often to a much greater extent than natural 
rewards (Di Chiara & Imperato, 1988). A wealth of evidence indicates that DA activity 
within these systems plays a pivotal in the reinforcing effects of drugs of abuse and their 
self-administration by laboratory animals (Koob, 1992; Pierce & Kumaresan, 2006).  
Firstly, all drugs of abuse share the capacity to increase synaptic concentrations of 
mesoaccumbal DA. Di Chiara and Imperato (1988) measured extracellular DA 
concentrations in freely moving rats after the administration of various drugs. Drugs that 
are abused such as amphetamine, cocaine, nicotine, and morphine, increased synaptic DA 
in the nucleus accumbens by up to 1000%, 330%, 225%, and 200%, respectively (Di 
Chiara & Imperato, 1988). Drugs that are not abused such as imipramine (anti-depressant), 
atropine (anti-muscarinic drug), and diphenhydramine (anti-histamine), did not increase 
synaptic DA concentration (Di Chiara & Imperato, 1988). This increase in synaptic DA 
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produced by drugs of abuse is directly related to the pattern of responding during self-
administration. Laboratory animals initially responded rapidly, greatly increasing 
extracellular dopamine levels; after this initial peak, DA levels were maintained at an 
elevated level for the duration of the session with sustained pressing (Hurd, Weiss, Koob, 
And, & Ungerstedt, 1989; Pettit & Justice, 1991; Ranaldi, Pocock, Zereik, & Wise, 1999; 
R. A. Wise et al., 1995). 
Secondly, drugs that selectively facilitate DA neurotransmission are self-
administered. Substitution of cocaine or amphetamine with selective DA agonists 
continues to maintain self-administration behaviour (Ranaldi, Wang, & Woolverton, 2001; 
Weed & Woolverton, 1995; Woolverton, Goldberg, & Ginos, 1984). Moreover, selective 
DA agonists alone are often readily self-administered by naïve animals (Howell & Byrd, 
1991; Nader & Mach, 1996; Self, Belluzzi, Kossuth, & Stein, 1996; Self & Stein, 1992; 
Weed & Woolverton, 1995; Yokel & Wise, 1978).  
Thirdly, pharmacological manipulation of the DA system influences self-
administration. Administration of DA agonists decreases self-administration of cocaine, 
amphetamine, or methamphetamine, producing a leftward shift in the dose effect curve 
(Barrett, Miller, Dohrmann, & Caine, 2004; Caine & Koob, 1994a; Munzar, Baumann, 
Shoaib, & Goldberg, 1999; Yokel & Wise, 1978). This compensatory responding is similar 
to what is seen when the self-administration infusion dose is increased (Goldberg, 
Hoffmeister, et al., 1971; Pickens & Harris, 1968; Weeks & Collins, 1964). Conversely, 
administration of DA antagonists produces a rightward shift in the dose effect curve for 
cocaine or amphetamine self-administration, represented by an increase in responding 
(Britton et al., 1991; Caine & Koob, 1994a; Corrigall & Coen, 1991a; Hubner & Edward 
Moreton, 1991; Koob, Le, & Creese, 1987; Phillips, Robbins, & Everitt, 1994; Risner & 
Jones, 1976; Yokel & Wise, 1976); similar to what is seen when the self-administration 
infusion dose is decreased (Goldberg, Hoffmeister, et al., 1971; Pickens & Harris, 1968; 
Weeks & Collins, 1964).  
Finally, destruction of dopamine nerve terminals in the mesoaccumbal DA system 
decreases drug self-administration. Lesions of the NAcc and the VTA with 6-
hydroxydopamine (6-OHDA) produced a long-lasting decrease in the self-administration 
of cocaine (Caine & Koob, 1994b; Roberts, Corcoran, & Fibiger, 1977; Roberts, Koob, 
Klonoff, & Fibiger, 1980; Roberts & Koob, 1982). The recovery of cocaine self-
administration was correlated with the level of DA depletion produced by the lesion; rats 
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with the greatest depletion of DA failed to recover cocaine self-administration at all 
(Roberts et al., 1980; Roberts & Koob, 1982). Lesions with 6-OHDA in the NAcc also 
produced long-lasting reductions in the self-administration of nicotine and amphetamine 
(Corrigall & Coen, 1991b; Lyness, Friedle, & Moore, 1979; Singer, Wallace, & Hall, 
1982). Further, the acquisition of amphetamine (Lyness et al., 1979) and heroin (Bozarth 
& Wise, 1986) self-administration was prevented by 6-OHDA lesions of the NAcc and 
VTA, respectively. 
In contrast to the role of DA, several lines of evidence indicate that 5-HT is 
inhibitory to the self-administration of drugs of abuse. Selective 5-HT agonists are not 
abused by humans nor are they self-administered by laboratory animals (Götestam & 
Andersson, 1975; Howell & Byrd, 1995; Roberts et al., 1999; Tessel & Woods, 1975; 
Vanover, Nader, & Woolverton, 1992). Roberts and colleagues tested various cocaine 
analogues that had a range of affinities for the DA and 5-HT transporters in self-
administration. They found that drugs with a higher affinity ratio for the DA transporter 
over the 5-HT transporter were more likely to be self-administered (Roberts et al., 1999). 
Similarly, Wee and colleagues tested a number of amphetamine analogues with similar 
potencies as in-vivo releasers of DA but differed in their potency for 5-HT release. They 
found that greater self-administration responding correlated with lower 5-HT release (Wee 
et al., 2005). d-amphetamine was the most readily self-administered drug and had a 
potency as a releaser of DA 220 times greater than 5-HT (Wee et al., 2005).  
Administration of various serotonin agonists decreased self-administration of 
amphetamine (Dianna, Smith, Smith, & Lyness, 1986; Porrino et al., 1989; Wee & 
Woolverton, 2006), methamphetamine (Munzar et al., 1999), cocaine (Carroll, Lac, 
Asencio, & Kragh, 1990a, 1990b; Czoty, Ginsburg, & Howell, 2002; Peltier & Schenk, 
1993; Richardson & Roberts, 1991), ethanol (Lyness & Smith, 1992), and heroin (Higgins, 
Wang, Corrigall, & Sellers, 1994; Y. Wang, Joharchi, Fletcher, Sellers, & Higgins, 1995). 
Wee and Woolverton (2006) mixed the 5-HT agonist, fenfluramine, with amphetamine at 
various doses and found that a higher ratio of fenfluramine:amphetamine, (i.e. 5-HT:DA 
release) was negatively correlated with self-administration responding. Increasing 5-HT 
levels by the administration of L-tryptophan, the amino acid precursor of 5-HT, decreased 
self-administration of cocaine (Carroll et al., 1990b; McGregor, Lacosta, & Roberts, 1993) 
and amphetamine (Lyness, 1983; Smith, Dianna, Smith, Leccese, & Lyness, 1986). 
Conversely, 5-HT depletion achieved by 5, 7-dihydroxytryptamine (5, 7-DHT) lesions or 
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pre-treatment with the 5-HT synthesis inhibitor, p-chlorophenylalanine (pCPA), facilitated 
self-administration of ethanol (Lyness & Smith, 1992), amphetamine (Fletcher, Korth, & 
Chambers, 1999; Leccese & Lyness, 1984; Lyness, Friedle, & Moore, 1980), MDMA 
(Bradbury et al., 2013), and morphine (Dworkin et al., 1988; Smith, Shultz, Co, Goeders, 
& Dworkin, 1987). 
5-HT projections originating from the dorsal and median raphe innervate virtually 
all parts of the central nervous system including the VTA, NAcc, and PFC (Di Matteo, Di 
Giovanni, Pierucci, & Esposito, 2008). 5-HTergic mechanisms can modulate DA 
neurotransmission within these structures by direct activation of 5-HT receptors located on 
DA neurons or via inhibitory-GABA and excitatory-glutamate mediated connections 
(Bankson & Cunningham, 2001; Di Matteo et al., 2008; Gudelsky & Yamamoto, 2008). 
Increasing extracellular 5-HT concentrations with a selective serotonin reuptake inhibitor 
(SSRI), administered at doses that decreased cocaine self-administration, also decreased 
cocaine-produced synaptic DA in the caudate nucleus (Czoty et al., 2002). Thus, it was 
suggested that the inhibitory effect of 5-HT on cocaine self-administration was due to its 
inhibitory effect on DA neurotransmission (Czoty et al., 2002). The relationship between 
5-HT and DA is complicated, however, as activation of several 5-HT receptors such as the 
5-HT1a, 5-HT1b, 5-HT2a, 5-HT2b, facilitate DA release whereas activation of the 5-HT2c 
receptor mediates an inhibitory effect on DA release (Reviewed by Di Matteo et al., 2008).  
It is evident that DA neurotransmission underlies the reinforcing effects of drugs of 
abuse and their self-administration by laboratory animals. In contrast, increased 5-HT 
neurotransmission appears to be inhibitory to the self-administration of drugs of abuse. 
Acute administration of MDMA increases synaptic concentrations of 5-HT to a far greater 
extent than DA (Green et al., 2003). Why then, is MDMA self-administered by non-human 
primates (Beardsley et al., 1986; Lamb & Griffiths, 1987), rats (Schenk, 2009), and mice 
(Trigo, Panayi, Soria, Maldonado, & Robledo, 2006), and why is it abused by humans 
(Cottler et al., 2009)? 
Neurochemical consequences of repeated MDMA exposure 
The answer to this question lies in an understanding of the changes in 5-HTergic 
and DAergic mechanisms that occur with repeated exposure to MDMA. Since the late 
1980’s, several studies have reported deficits in 5-HT neurotransmission following 
repeated MDMA exposure. Repeated experimenter-administered injections of MDMA (10 
– 40 mg/kg, twice daily, for 4 days) produced dose-dependant reductions in rat brain 5-HT 
ROLE OF D2 RECEPTORS IN MDMA SENSITISATION 
19 
 
(Battaglia, Yeh, & De Souza, 1988; Commins et al., 1987; O’Hearn, Battaglia, De Souza, 
Kuhar, & Molliver, 1988), 5-HIAA (Battaglia, Yeh, et al., 1988; Battaglia et al., 1987), 
and decreased 5-HT uptake sites (Battaglia, Yeh, et al., 1988; Battaglia et al., 1987; 
Commins et al., 1987). Synaptic overflow of striatal 5-HT was also diminished following 
repeated MDMA exposure (10 mg/kg × 4; Shankaran & Gudelsky, 1999). Even single 
injections of MDMA (10 – 40 mg/kg) produced reductions in rat brain 5-HT (Mokler, 
Robinson, & Rosecrans, 1987; Schmidt, 1987; Stone, Merchant, Hanson, & Gibb, 1987), 
5-HIAA (Mokler et al., 1987; Stone et al., 1987), tryptophan hydroxylase activity (Stone et 
al., 1987), and 5-HT uptake sites (Schmidt, 1987). These effects appear to be due to the 
extreme effect of MDMA on the 5-HT system since co-administration of the SSRIs, 
citalopram (Battaglia, Yeh, et al., 1988), or fluoxetine (Schmidt, 1987) prevented the 
development of 5-HTergic deficits. Following repeated MDMA exposure, 5-HT deficits 
have also been demonstrated in guinea pigs (Commins et al., 1987), non-human primates 
(Insel, Battaglia, Johannessen, Marra, & De Souza, 1989; Kleven, Woolverton, & Seiden, 
1989; Ricaurte, DeLanney, Irwin, & Langston, 1988; Wilson, Ricaurte, & Molliver, 1989), 
and even humans (McCann, Ridenour, Shaham, & Ricaurte, 1994; McCann, Szabo, 
Scheffel, Dannals, & Ricaurte, 1998; Semple, Ebmeier, Glabus, O’Carroll, & Johnstone, 
1999; Ralph Thomasius et al., 2003; Verkes et al., 2001). In rats, these 5-HTergic deficits 
take several months to fully recover (Battaglia, Yeh, et al., 1988; Scanzello, 
Hatzidimitriou, Martello, Katz, & Ricaurte, 1993) whereas in non-human primates and 
humans, 5-HT deficits last for several years (Ricaurte, Martello, Katz, & Martello, 1992; 
R. Thomasius et al., 2006). 
The use of relatively high doses of non-contingent MDMA has have led to some 
controversy over the relevance of these findings for human MDMA use (see Baumann, 
Wang, & Rothman, 2007; de la Torre & Farré, 2004; Ricaurte, McCann, Szabo, & 
Scheffel, 2000). Studies investigating 5-HTergic deficits following self-administered 
MDMA offer better external validity. Lower densities of 5-HT uptake sites (Schenk et al., 
2007) and decreased 5-HT tissue levels (Do & Schenk, 2013) were found in MDMA self-
administering rats. Tissue levels had decreased by ~35% two weeks following cessation of 
self-administration but had recovered by ten weeks (Do & Schenk, 2013). MDMA-
produced synaptic overflow of NAcc 5-HT was also decreased following 20 days of 
MDMA self-administration (Reveron et al., 2010). Deficits appear to be dependent on 
exposure levels, however, as self-administration of smaller amounts of MDMA failed to 
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significantly decrease 5-HT tissue levels or 5-HT uptake sites in rats (Do & Schenk, 2013) 
or rhesus monkeys (Banks et al., 2008; Fantegrossi et al., 2004).  
While a considerable amount of evidence indicates that 5-HT neurotransmission 
decreases with repeated MDMA exposure, some studies have found that repeated MDMA 
exposure enhanced DAergic activity. Tissue levels of DA were increased four weeks after 
repeated MDMA exposure (Mayerhofer, Kovar, & Schmidt, 2001). The capacity for 
MDMA (Kalivas, Duffy, & White, 1998) and cocaine (Morgan, Horan, Dewey, & Ashby 
Jr., 1997) to produce increases in NAcc DA was significantly enhanced for rats previously 
treated MDMA (20 mg/kg × 4, over 4 days). Intermittent dosing appears critical to the 
development of this sensitised DAergic response, however, as when 40 mg/kg was 
administered over a single day there were no changes (Shankaran & Gudelsky, 1999). 
MDMA-(10 mg/kg) produced synaptic striatal DA was significantly increased for rats that 
met an acquisition criteria for MDMA self-administration (Colussi-Mas et al., 2010). 
Following the self-administration of a lower amount of MDMA, however (average of ~100 
mg/kg compared to 165 mg/kg in the former study), synaptic NAcc DA produced by a 
self-administered infusion of MDMA (3 mg/kg) was unchanged (Reveron et al., 2010). 
Implications for MDMA self-administration. As with other drugs of abuse, 
increased 5-HT neurotransmission is inhibitory to the reinforcing effects of MDMA. Rats 
with a greater NAcc 5-HT response to MDMA were less likely to subsequently acquire 
MDMA self-administration (Bradbury et al., 2013). It is not surprising, then, that 
manipulations that decreased MDMA-stimulated 5-HT increased the reinforcing effects of 
MDMA. Both neurotoxic 5-7 DHT lesions (Bradbury et al., 2013) and a genetic mutation 
of the 5-HT transporter (Oakly et al., 2013) decreased the latency to acquire MDMA self-
administration and increased the percentage of rats that met acquisition criteria; rendering 
the acquisition profile of MDMA self-administration more comparable to other 
psychostimulant drugs of abuse. These findings suggest that MDMA-produced increases 
in 5-HT limits the acquisition of MDMA self-administration.  
Although MDMA preferentially facilities 5-HT neurotransmission, evidence 
suggests that the reinforcing effects of MDMA, as with other drugs of abuse, are mediated 
by DAergic mechanisms. S(+)-MDMA, the more potent DA releasing isomer of MDMA, 
was more readily self-administered by rhesus monkeys than R(-)-MDMA, the less potent 
DA releasing isomer; racemic (±)-MDMA fell in between the two enantiomers (Johnson, 
Hoffman, & Nichols, 1986; Z. Wang & Woolverton, 2007). In rats, treatment with DA 
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receptor antagonists produced a rightward shift in the dose-response curve for MDMA 
self-administration (Brennan, Carati, Lea, Fitzmaurice, & Schenk, 2009; Daniela et al., 
2004). Perhaps the most compelling piece of evidence is that rats that met an acquisition 
criteria for MDMA self-administration displayed greater MDMA-produced synaptic 
striatal DA compared to rats that failed to acquire (Colussi-Mas et al., 2010). This suggests 
that the development of a sensitised DAergic response might be critical to the acquisition 
of MDMA self-administration.  
Our working hypothesis is that repeated MDMA exposure results in 5-HTergic 
deficits and DA sensitisation, neuroadaptations that, for the reasons discussed above, 
would be expected to enhance the reinforcing efficacy of MDMA. These neuroadaptations 
facilitate the eventual acquisition of self-administration of MDMA, contributing to the 
progressive escalation of MDMA intake, which in turn, leads to further neuroadaptations, 
and so on (Schenk, 2011). Thus, with repeated exposure, the pharmacological profile of 
MDMA begins to become more similar to other drugs of abuse such as amphetamine or 
cocaine. The influence of 5-HTergic mechanisms on the acquisition of MDMA self-
administration has already received some attention (see above). The influence of DAergic 
mechanisms, however, is less understood and was the premise for the present thesis.  
Behavioural sensitisation  
One way to investigate the neuroadaptations produced by repeated drug exposure is 
to study the corresponding changes in behaviour. Some drug-produced behaviours may 
decrease (become tolerant) whereas other behaviours can increase (beceome sensitised; 
Stewart & Badiani, 1993). The latter phenomenon was first reported in the 1930’s (Downs 
& Eddy, 1932a, 1932b; Seevers & Tatum, 1931) and refers to the progressive and 
persistent increase in drug-produced behaviour that occurs with repeated exposure to some 
drugs. Sensitisation of several behaviours including sniffing, head movements, and rearing 
have been reported in rats although the most commonly measured behaviour is locomotor 
activity (Pierce & Kalivas, 1997; Post & Rose, 1976; Robinson, 1984; Stewart & Badiani, 
1993). 
Behavioural sensitisation is characterised by two phases: the development of 
sensitisation and the expression of sensitisation. The development of sensitisation (also 
called the initiation, or induction of sensitisation) typically involves a regimen of repeated 
intermittent drug exposure followed by a withdrawal period of at least one day (Pierce & 
Kalivas, 1997). However, in some cases even a single injection has been sufficient to 
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induce sensitisation (Vanderschuren, Schmidt, et al., 1999). The expression of sensitisation 
refers to the manifestation of the sensitised behavioural response produced by the 
subsequent re-exposure to the drug (Pierce & Kalivas, 1997). A greater behavioural 
response in drug treated animals compared to vehicle treated controls indicates the 
development of a sensitised response (i.e. a leftward shift in the dose response curve).  
Behavioural sensitisation has been observed following repeated administration of 
several different psychostimulants including amphetamine, cocaine, methylphenidate, and 
MDMA, as well as other types of drugs including opioids, nicotine, and ethanol (for 
reviews see Kalivas & Stewart, 1991; Pierce & Kalivas, 1997; Robinson & Becker, 1986; 
Vanderschuren & Kalivas, 2000). Repeated exposure to some drugs can also result in 
cross-sensitisation to the behavioural effects of other drugs, suggesting the involvement of 
similar neural systems (Kalivas & Stewart, 1991; Pierce & Kalivas, 1997; Robinson & 
Becker, 1986; Vanderschuren & Kalivas, 2000). 
The relationship between central DAergic neurotransmission and motor activity has 
long been known (Carlsson, Lindqvist, Magnusson, & Waldeck, 1958; Costall & Naylor, 
1979; Hornykiewicz, 1966; Ungerstedt, 1979). The capacity of a drug to produce 
locomotor hyperactivity is dependent on its capacity to facilitate DA neurotransmission; 
drugs with a greater effect on DA generally produce a greater effect on locomotor activity 
(Hurd et al., 1989; Steinpreis & Salamone, 1993). It is not surprising, then, that 
sensitisation of locomotor activity is mirrored by the sensitisation of central DAergic 
mechanisms (Kalivas & Stewart, 1991; Pierce & Kalivas, 1997; Vanderschuren & Kalivas, 
2000). Behavioural sensitisation has, therefore, often been used to investigate changes in 
DAergic functioning produced by repeated drug exposure (see Kalivas & Stewart, 1991; 
Vanderschuren & Kalivas, 2000).   
Sensitisation and the acquisition of self-administration  
The DAergic neuroadaptations underlying behavioural sensitisation have been 
proposed to underlie several aspects of addiction. One function of the central DAergic 
system is to attribute incentive salience to stimuli, imbuing them with salience and making 
them ‘wanted’ (Berridge & Robinson, 1998; Robinson & Berridge, 1993; Roy A Wise, 
2004). The incentive-sensitisation theory of addiction suggests that repeated use of 
addictive drugs leads to the sensitisation of this neural system which renderers some 
individuals hypersensitive to the drug, the act of drug taking, and drug associated stimuli 
(Robinson & Berridge, 1993). Thus, it is the sensitisation of incentive salience towards 
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drugs and drug-related stimuli that transforms ordinary ‘wanting’ into excessive drug 
craving (Robinson & Berridge, 1993). Given that sensitised central DAergic mechanisms 
have been implicated in the compulsive drug-taking and drug-seeking behaviour 
characteristic of addiction, sensitisation has been extensively studied in the context of self-
administration.   
The acquisition of self-administration of many drugs is dose-dependent; self-
administration of higher doses is typically acquired with a shorter latency than when lower 
doses serve as the reinforcer (Carroll & Lac, 1997; Schenk et al., 1993). Much like 
increasing the dose, exposing animals to a sensitising pre-treatment regimen of drug 
exposure shifts the acquisition curve for self-administration to the left (sensitisation). Low 
doses of amphetamine and cocaine, that were normally subthreshold as a reinforcer, were 
reliably self-administered in rats pre-treated with amphetamine (Piazza et al., 1991; Piazza, 
Deminiere, le Moal, & Simon, 1990; Piazza, Deminière, Le Moal, & Simon, 1989; Pierre 
& Vezina, 1997; Vezina, Lorrain, Arnold, Austin, & Suto, 2002) or cocaine, (Horger, 
Shelton, & Schenk, 1990; Zhao & Becker, 2010), respectively. When higher doses are 
used, acquisition of self-administration amphetamine does not appear to be influenced by 
prior exposure (Lorrain, Arnold, & Vezina, 2000; Mendrek, Blaha, & Phillips, 1998). 
However, because virtually all rats acquire self-administration of higher doses of 
amphetamine within a few days, a ceiling effect would likely conceal a significant finding. 
Indeed, when tested under a progressive ratio schedule, where the fixed ratio required to 
earn an infusion progressively increases, rats pre-treated with amphetamine worked harder 
in order to obtain an infusion suggesting an increase in the reinforcing efficacy of 
amphetamine (Lorrain et al., 2000; Mendrek et al., 1998; Vezina et al., 2002). Pre-
treatment with ethanol has been shown to facilitate the subsequent acquisition of ethanol 
self-administration (Camarini & Hodge, 2004; Rodd-Henricks et al., 2002). Further, 
repeated exposure to amphetamine, MDMA, caffeine, and nicotine, facilitated the 
acquisition of cocaine self-administration indicating cross-sensitisation (Fletcher, 
Robinson, & Slippoy, 2001; Horger, Giles, & Schenk, 1992; Horger, Wellman, Morien, 
Davies, & Schenk, 1991; Valadez & Schenk, 1994). 
Evidence suggests that the same sensitised DAergic mechanisms underlying 
behavioural sensitisation are implicated in the sensitised acquisition of self-administration 
(Vezina, 2004). Firstly, only pre-treatment regimens that result in behavioural / DAergic 
sensitisation facilitated subsequent self-administration. For example, repeated 
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administration of amphetamine systemically or directly into the VTA produced 
behavioural and DAergic sensitisation (Cador, Bjijou, & Stinus, 1995; Kalivas & Weber, 
1988; Vezina, 1993) and facilitated subsequent amphetamine self-administration (Vezina 
et al., 2002). Repeated amphetamine administration directly into the NAcc, however, did 
not result in sensitisation (Cador et al., 1995; Kalivas & Weber, 1988) nor did it facilitate 
subsequent drug-taking (Vezina et al., 2002). Secondly, procedures that prevent the 
development of behavioural and DAegric sensitisation also prevent the subsequent 
facilitation of drug taking. For example, treatment with a D1 antagonist blocked the 
development of amphetamine sensitisation (Vezina & Stewart, 1989; Vezina, 1996) and 
blocked the subsequent facilitation of self-administration (Pierre & Vezina, 1998).  
The present thesis 
Acute behavioural effects of MDMA. As with many other drugs of abuse, acute 
administration of MDMA produces dose-dependent increases in locomotor hyperactivity 
(Brennan & Schenk, 2006; Gold, Koob, & Geyer, 1988; Spanos & Yamamoto, 1989) by 
virtue of the drug’s effects on DA neurotransmission. MDMA-produced hyperactivity was 
mirrored by increased synaptic overflow of DA (Baumann, Clark, & Rothman, 2008) and 
was attenuated following 6-OHDA lesions (Gold, Hubner, & Koob, 1989). Moreover, 
administration of D1 and D2 antagonists dose-dependently attenuated MDMA-produced 
locomotor activity (Brennan et al., 2009; Bubar, Pack, Frankel, & Cunningham, 2004; 
Daniela et al., 2004), an effect that correlated with attenuated firing of striatal motor 
neurons (Ball, Budreau, & Rebec, 2003). 
MDMA-produced increases in 5-HT neurotransmission also influence MDMA-
produced hyperactivity. 5-HT depletion achieved through 5, 7-DHT lesions or pCPA 
administration decreased MDMA-produced locomotion (Callaway, Wing, & Geyer, 1990; 
Kehne et al., 1996). Administration of 5-HT1a (Callaway, Rempel, Peng, & Geyer, 1992; 
Kehne et al., 1996; McCreary, Bankson, & Cunningham, 1999) and 5-HT2a (Ball & Rebec, 
2005; Herin, Liu, Ullrich, Rice, & Cunningham, 2005; Kehne et al., 1996) antagonists 
attenuated MDMA-produced locomotion whereas 5-HT2c (Bankson & Cunningham, 2002; 
Fletcher, Sinyard, & Higgins, 2006; Gold & Koob, 1988) antagonists potentiated MDMA-
produced locomotion. With many 5-HT receptors influencing DA neurotransmission (Di 
Matteo et al., 2008), MDMA-produced increases in 5-HT may contribute to MDMA-
produced hyperactivity via interactions between these two neurotransmitter systems (Ball 
& Rebec, 2005; Bankson & Cunningham, 2001).  
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The pattern of hyperactivity produced by MDMA differs from that of other 
psychostimulants in that it is typically restricted to the periphery of a closed chamber 
(Bradbury, Gittings, & Schenk, 2012; Gold et al., 1988; Ludwig, Mihov, & Schwarting, 
2008; McCreary et al., 1999; Palenicek, Votava, Bubenikova, & Horacek, 2005). In 
contrast, drugs that preferentially facilitate DA neurotransmission such as amphetamine 
produce activity that is more generally distributed over the entire chamber (Bradbury et al., 
2012; Geyer, Russo, & Masten, 1986; Gold, Koob, & Geyer, 1990). It has been suggested 
that the thigmotaxic response produced by MDMA is due the preferential effect of MDMA 
on 5-HT neurotransmission (Gold & Koob, 1988).  
While horizontal locomotion is increased by MDMA administration, vertical 
locomotion (i.e. rearing activity) is generally suppressed by MDMA (Callaway et al., 
1990; Fone et al., 2002; Kehne et al., 1996; Ludwig et al., 2008; Sadananda, Natusch, 
Karrenbauer, & Schwarting, 2012; M. R. Thompson, Callaghan, Hunt, Cornish, & 
McGregor, 2007). Gold and colleagues, however, found that although MDMA attenuated 
rearing during the initial 30 min, the highest dose of MDMA (10 mg/kg) potentiated 
rearing 90 min following MDMA administration (Gold et al., 1988).  
Relatively fewer studies have investigated the neurochemical underpinnings of 
rearing activity compared to horizontal locomotion, although evidences suggests that 
increased DAergic activity also underlies rearing activity. Basal rearing activity was 
attenuated by a D1 antagonist (Hoffman & Beninger, 1985). DA injected into the NAcc 
produced rearing activity, which was dose-dependently attenuated by the endogenous 
neuropeptide, neurotensin (Kalivas, Nemeroff, & Prange, 1984). Rearing activity that was 
produced by a D1 agonist was blocked by D1 and D2 receptor antagonists (Molloy & 
Waddington, 1985). Further, decreasing extracellular DA in the NAcc via retrodialysis of 
nociceptin attenuated cocaine-produced rearing (Vazquez-DeRose et al., 2013). 
Interestingly, although racemic ±MDMA typically supressing rearing, S(+)-MDMA, the 
more potent DA releasing isomer, facilitated rearing (Bubar et al., 2004; Herin et al., 2005; 
McCreary et al., 1999), which suggests that increased DA plays a role in MDMA-
produced rearing activity. Indeed, both D1 and D2 antagonists attenuated S(+)-MDMA-
produced rearing activity (Bubar et al., 2004).  
5-HT may also play a role in mediating rearing behaviour, possibly via interactions 
with DA neurons. Administration of 5-HT into the dorsal raphe attenuated rearing 
(Hillegaart, 1990). Administration of 5-HT1a (Hillegaart, Estival, & Ahlenius, 1996; 
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Hillegaart, Wadenberg, & Ahlenius, 1989; Hillegaart, 1990; Sadananda et al., 2012) or 5-
HT2a/c agonists (Hillegaart et al., 1996) also decreased rearing. MDMA-supressed rearing, 
however, was not affected by 5-HT2a antagonists, haloperidol (nonselective D2 antagonist), 
or SSRI treatment (Callaway et al., 1990; Kehne et al., 1996).  
Experiment 1: MDMA-induced behavioural sensitisation. Repeated, intermittent, 
MDMA exposure can result in the sensitisation of these acute behavioural responses. 
Locomotor activity was enhanced following repeated experimenter- (Bradbury et al., 2012; 
Colussi-Mas & Schenk, 2008; Kalivas et al., 1998; Spanos & Yamamoto, 1989) and self-
administered MDMA (Schenk & Bradbury, 2015). Locomotor activity in the centre of the 
activity chamber was specifically sensitised (Bradbury et al., 2012; Colussi-Mas & 
Schenk, 2008; Ludwig et al., 2008; McCreary et al., 1999). Following repeated 
experimenter- (Ludwig et al., 2008) and self-administered (Schenk & Bradbury, 2015) 
MDMA, rearing activity produced by MDMA was also increased.  
As with other drugs of abuse, DAergic mechanisms appear to play an important 
role in MDMA sensitisation. Repeated MDMA exposure that produced behavioural 
sensitisation was accompanied by sensitised DAergic responses in the NAcc (Kalivas et 
al., 1998) and changes in accumbal c-Fos expression (Colussi-Mas & Schenk, 2008). 
Moreover, repeated MDMA exposure resulted in cross sensitisation to other, more potent, 
DAergic drugs including amphetamine, and cocaine (Bradbury et al., 2012; Kalivas et al., 
1998). Little is known about the specific DA receptor mechanisms involved in MDMA 
sensitisation, however.  
There are two families of DA receptors: D1-like receptors, which include the D1 
and D5 receptors, and D2-like receptors, which include the D2, D3, and D4 receptors 
(Missale, Nash, Robinson, Jaber, & Caron, 1998). These two families of DA receptors 
differ in their physiological functioning (Kebabian & Calne, 1979). D1-like receptors are 
coupled to the G protein, Gs, which subsequently activates adenylyl cyclase, facilitating 
cyclic adenosine monophosphate (cAMP) activity (Missale et al., 1998). In contrast, D2-
like receptors are coupled to Gi, which inhibits adenylyl cyclase and thus inhibits cAMP 
activity (Missale et al., 1998). Further, D2 receptors can function as post-synaptic receptors 
(genetically long isoform) but also as auto-receptors (genetically short isoform), which 
modulate DA synthesis and release (Beaulieu & Gainetdinov, 2011).  
The D1 antagonist, SCH-23390, failed to block the development of MDMA 
sensitisation but blocked the expression when administered systemically or when injected 
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directly into the NAcc (Ramos, Goñi-Allo, & Aguirre, 2004). The expression of MDMA 
sensitisation was also blocked when SCH-23390 was injected into the medial PFC, 
however, the authors concluded this effect was due to agonism of 5-HT2c receptors 
(Ramos, Goñi-Allo, & Aguirre, 2005), of which SCH-23390 has fairly good affinity 
(Briggs et al., 1991; Millan, Newman-Tancredi, Quentric, & Cussac, 2001). We have 
previously shown that repeated MDMA exposure produced cross-sensitisation to the 
locomotor activating effects of the D1 agonist, SKF-81297, and the D2/3 agonist, quinpirole 
(Bradbury et al., 2012). Together, these findings suggest that both D1 and D2-like receptors 
are implicated in the expression of MDMA sensitisation but D1 receptors are not critically 
involved in the development of MDMA sensitisation. 
The first experiment of the present thesis will, therefore, investigate the 
contribution of D2 receptors to the development of MDMA behavioural sensitisation. 
Locomotor (total, centre, and peripheral) and rearing activity will be measured during a 
five-day MDMA pre-treatment regimen previously shown to induce behavioural 
sensitisation and during the subsequent test for the expression of MDMA sensitisation 
following two days of withdrawal (Bradbury et al., 2012; Colussi-Mas & Schenk, 2008). 
The effect of MDMA pre-treatment, with or without co-administration of the selective D2 
antagonist, eticlopride will be determined. It is hypothesised that eticlopride will block the 
development of MDMA-produced behavioural sensitisation. 
Experiment 2: Acquisition of MDMA self-administration. We have previously 
suggested that the development of a sensitised DAergic response to MDMA is critical to 
the acquisition of reliable MDMA self-administration (Schenk, 2011). In support of this 
idea, rats that met acquisition criteria for MDMA self-administration displayed increased 
MDMA-produced synaptic striatal DA compared to rats that failed to acquire. Because 
behavioural sensitisation induced by repeated MDMA exposure was accompanied by 
enhanced MDMA-produced NAcc DA release (Kalivas et al., 1998), and the reinforcing 
effects of MDMA have been attributed to DAergic mechanisms (Brennan et al., 2009; 
Daniela et al., 2004), repeated MDMA exposure would also be expected to sensitise the 
reinforcing effects of MDMA. Thus, the second experiment of the present thesis will 
investigate the effect of a sensitising pre-treatment regimen of MDMA exposure on the 
subsequent acquisition of MDMA self-administration. If the development of a sensitised 
response to MDMA is a critical determinant of MDMA self-administration, then pre-
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treatment would be expected to increase the percentage of rats that subsequently acquire 
MDMA self-administration.  
Because the DAergic mechanisms underlying sensitisation to the locomotor 
activating and reinforcing effects of drugs of abuse are thought to be similar (Vezina, 
2004), the contribution of D2 receptor mechanisms will also be investigated. The effects of 
MDMA pre-treatment, with or without eticlopride, on the subsequent acquisition of 
MDMA self-administration will be determined. Manipulations that prevent the 
development of sensitisation to other drugs of abuse also typically prevent the subsequent 
facilitation of self-administration (Pierre & Vezina, 1998). Therefore, if eticlopride 
prevents the development of MDMA sensitisation (experiment 1), it is expected that it 
would also prevent the hypothesised facilitation of MDMA self-administration following 
MDMA pre-treatment.  
High dose regimens of repeated MDMA exposure produce 5-HT deficits (Baumann 
et al., 2007), which would also be expected to facilitate the acquisition of MDMA self-
administration (Bradbury et al., 2013; Oakly et al., 2013). Thus, in order to focus on 
DAergic sensitisation, the dosing regimen used in the present thesis will use relatively 
lower doses of MDMA that have previously been shown not to produce decreases in 5-HT 
tissue levels (Bradbury et al., 2012) but still produced reliable behavioural sensitisation 
(Bradbury et al., 2012; Colussi-Mas & Schenk, 2008).  
Method 
Subjects 
Male Sprague-Dawley rats were bred in the vivarium at Victoria University of 
Wellington and housed in groups of four until they weighed 280 – 300 g. Thereafter, rats 
were housed individually in polycarbonate hanging cages in a temperature- (19-21oC) and 
humidity- (55%) controlled environment. Food and water were available ad libitum at all 
times except during testing. The housing colony was maintained on a 12 hour light/dark 
cycle (lights on at 0700) with testing conducted during the light portion of the cycle. All 
experimental protocols were approved by the Animal Ethics Committee of Victoria 
University of Wellington.  
Surgery 
For self-administration experiments, 280 – 300 g rats were housed individually for 
at least one week prior to being surgically implanted with intravenous (i.v.) catheters. 
Deep anaesthesia was produced by an intraperitoneal (i.p.) injection of a solution 
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combining ketamine (90.0 mg/kg, PhoenixPharm, Auckland, New Zealand) and xylazine 
(9.0 mg/kg, Provet, Palmerston North, New Zealand) followed by a subcutaneous (s.c.) 
injection of the anti-inflammatory analgesic, Carprofen (5 mg/kg, Pfizer Animal Health, 
Auckland, New Zealand). Lacrilube® was applied to both eyes to prevent corneal 
desiccation. The external jugular vein was isolated and tied of at its anterior end using 
sterile thread. A Silastic® catheter (0.51 mm I.D., 1.34 mm O.D.) was inserted, advanced 
posteriorly towards the atrium, and secured in place with sterile thread. The distal end of 
the catheter, fitted with a 2 cm piece of 22 gauge stainless steel tubing, was routed 
subcutaneously to an exposed part of the skull where it was fixed in place using four 
jewellers screws embedded in dental acrylic. Hartmann’s solution (2 × 5 ml, s.c.) was 
administered post-surgery to restore electrolyte balance. Daily Carprofen injections (5.0 
mg/kg, s.c.) were administered for two days following surgery and the catheter was 
flushed daily with 0.2 ml of sterile 0.9% saline solution containing heparin (30 IU/ml) and 
penicillin (250 000 IU/ml) to prevent blood coagulation and infection.  
Apparatus 
Locomotor activity was measured in clear Plexiglas chambers (Med Associated 
Inc, USA; model ENV-515) measuring 42 × 42 × 30 cm, set in sound-attenuating boxes. 
The chambers each contained two sets of 16 infra-red sensors spaced 2.5 cm apart 
producing a lattice of beams 1.7 cm above the floor of the chamber. The sequential 
interruption of three beams (the approximate size of the body of a rat) was recorded as one 
locomotor activity count. For data collection, the chambers were divided into two areas: 
the central zone was defined as the central 19 × 19 cm and the remaining area was defined 
as the periphery. Another series of beams spaced 2.5 cm apart, 15 cm above the floor of 
the chamber were used to record vertical activity (rearing). Any interruption of at least one 
of these beams was recorded as one rearing count. A white-noise generator was used to 
mask any outside noise. To control for olfactory confounds, chambers were washed with 
Virkon ‘S’ disinfectant (Southern Veterinary Supplies, NZ) after each session. All 
locomotor experiments were run in a temperature- (19-21oC) and humidity- (55%) 
controlled dark room, except for a dim red light that was used to illuminate the room 
during drug administrations.  
Self-administration testing was conducted in standard operant chambers equipped 
with two levers (Med Associated Inc, USA; model ENV-001). Responses on the active 
lever resulted in a 0.1 ml infusion of MDMA (1.0 or 0.5 mg/kg) delivered over a period of 
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12 seconds and the concurrent illumination of a light located above the lever. Responses 
on the inactive lever were recorded but produced no programmed consequence. A 20 ml 
syringe housed in a mechanical pump (Med Associated Inc, USA; model – PHM-100A) 
was connected through a swivel apparatus to a length of microbore tubing and attached to 
the  i.v. catheter. Drug delivery and data acquisition were controlled by the Med PC 
software. Self-administration testing was conducted within a temperature- (19-21oC) and 
humidity- (55%) controlled dark room.  
Experiment 1: procedure 
 On each of five daily pre-treatment sessions, rats received eticlopride (0.0, 0.05, or 
0.3 mg/kg i.p.) and were immediately placed into the activity chambers for 30 min prior to 
receiving MDMA (0.0 or 10.0 mg/kg i.p.). Thereafter, locomotor (total, centre, and 
peripheral), and rearing activity were measured for 60 min. Two days following the last 
pre-treatment session (day 8), the locomotor activating response to MDMA (5.0 mg/kg, 
i.p.) was determined. During these tests, rats were placed into activity chambers and 
received MDMA after a 30 min period. Locomotor (total, centre, and peripheral) and 
rearing activity was recorded for 30 min prior to, and for 60 min following the 
administration of MDMA. This dosing regimen of MDMA was selected as we have 
previously demonstrated that it produces reliable sensitisation to the locomotor-activating 
effects of MDMA (Bradbury et al., 2012; Colussi-Mas & Schenk, 2008). The MDMA 
challenge dose selected has been shown to reliably produce the expression of sensitisation, 
while being low enough to avoid ceiling effects (Bradbury et al., 2012; Colussi-Mas & 
Schenk, 2008). These doses of eticlopride were used based on previous literature (Brennan 
et al., 2009; Bubar et al., 2004; Vezina, 1996; White, Joshi, Koeltzow, & Hu, 1998). This 
protocol is summarised in Table 2. 
 
Table 2. 
Summary of experiment 1 protocol  
Days 1-5 Day 8  
Eticlopride MDMA Locomotor challenge Sample size (n) 
Saline Saline MDMA (5.0 mg/kg) n = 10 
Saline 10.0 mg/kg MDMA (5.0 mg/kg) n = 11 
0.05 mg/kg Saline MDMA (5.0 mg/kg) n = 8 
0.05 mg/kg 10.0 mg/kg MDMA (5.0 mg/kg) n = 7 
0.3 mg/kg Saline MDMA (5.0 mg/kg) n = 8 
0.3 mg/kg 10.0 mg/kg MDMA (5.0 mg/kg) n = 8 
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Experiment 2: procedure 
Approximately one week following surgery, pre-treatment began, as above, with 
the exclusion of the 0.05 mg/kg eticlopride dose. Following two days of withdrawal, 
instead of receiving a locomotor challenge, these animals began self-administration testing 
(day 8). Daily 2 hr sessions were conducted, six days per week. Prior to, and immediately 
after each session, catheters were flushed with 0.2 ml of the penicillin-heparin solution. 
Every 7th day, catheter patency was confirmed by the immediate loss of the righting reflex 
following administration of sodium pentobarbital (22.5 mg/kg, i.v.). Because of the nature 
of the study, catheters were unable to be repaired or replaced without interrupting the 
acquisition process. Thus, rats that failed to retain patent catheters were omitted from any 
further testing or analysis. Each session commenced with an experimenter-administered 
infusion of MDMA (1.0 mg/kg) to clear the catheter of the penicillin-heparin solution. 
Thereafter, MDMA (1.0 mg/kg) infusions were delivered according to an FR-1 schedule of 
reinforcement. As in our previous studies (Schenk et al., 2012), acquisition of MDMA 
self-administration was defined as the self-administration of at least 90 MDMA (1.0 
mg/kg) infusions within 25 test sessions.  
For rats that met acquisition criteria, the infusion dose of MDMA was decreased to 
0.5 mg/kg until a further 150 infusions had been self-administered. Rats that meet this 
second criterion remained in their home cages for two days of withdrawal before the 
locomotor activating effect of MDMA (5 mg/kg, i.p.) was measured. During these tests, 
rats were placed into activity chambers and received MDMA after a 30 min period. 
Locomotor activity was recorded for 60 min following the administration of MDMA. This 




Summary of experiment 2 protocol 
Days 1-5 Day 8+  
Eticlopride MDMA 
 MDMA self-administration 









MDMA 5mg/kg n = 12 
Saline 10.0 mg/kg 1.0 mg/kg 0.5 mg/kg MDMA 5mg/kg n = 12 
0.3 mg/kg Saline 1.0 mg/kg 0.5 mg/kg MDMA 5mg/kg n = 12 
0.3 mg/kg 10.0 mg/kg 1.0 mg/kg 0.5 mg/kg MDMA 5mg/kg n = 12 
 




MDMA HCl (±3,4-methylenedioxymethamphetamine hydrochloride; ESR Porirua, 
New Zealand) was dissolved in sterile 0.9% saline and injected at a volume of 1 mg/ml, 
i.p. For i.v. self-administration infusions, MDMA was dissolved in 3 IU/ml heparinised 
0.9% saline. S-(−)-Eticlopride hydrochloride (Sigma-Aldrich Castle Hill, Australia) was 
dissolved in sterile 0.9% saline solution and injected at a volume of 1 mg/ml, i.p. All drug 
weights refer to the salt.  
Data analysis 
Experiment 1. Individual two-way mixed measures analysis of variance (ANOVA) 
were conducted to analyse total, centre, and peripheral locomotor activity data during the 
five pre-treatment sessions as a function of pre-treatment. To investigate the relative 
change in centre and peripheral activity over the five pre-treatment sessions, these data 
were also calculated as a percentage change from baseline (group average from session 1) 
and analysed using a 2 (box zone: centre, periphery) × 5 (session: 1-5) repeated measures 
ANOVA. The locomotor challenge data were analysed using separate 3 (eticlopride dose: 
0.0, 0.05, 0.3) × 2 (MDMA dose: 0.0, 10.0) ANOVAs on total, centre, and peripheral 
locomotor activity data. Due to technical difficulties, rearing data from experiment 1 were 
not available.  
Experiment 2. Individual two-way mixed measures ANOVA’s were conducted to 
analyse total, centre, peripheral and rearing activity data during the five pre-treatment 
sessions as a function of pre-treatment. To investigate the relative change in centre and 
peripheral activity over the five pre-treatment sessions, these data were also calculated as a 
percentage change from baseline (group average from session 1) and analysed using a 2 
(box zone: centre, periphery) × 5 (session: 1-5) repeated measures ANOVA. Due to loss of 
catheter patency, only 6 - 9 rats per pre-treatment group finished the self-administration 
experiment. Therefore, only data from these rats were included in further analysis. For 
each rat that met acquisition criteria, the number of inactive and active lever responses 
were averaged over the first three days of self-administration and over the final three days 
prior to meeting criteria. A 2 (lever: inactive, active) × 2 (time: first 3 days, last 3 days) 
repeated measures ANOVA was conducted to test a preference for the active lever. The 
number of sessions to reach acquisition criteria was determined for each rat and the 
cumulative percentage of rats that met the criterion was determined as a function of test 
session for each pre-treatment group. Kaplan-Meier survival analyses (log-rank tests) were 
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used to compare the effect of pre-treatment on the cumulative percentage of rats that met 
the acquisition criterion for MDMA self-administration as a function of test session. Right-
censoring was applied to the data for rats that did not meet the acquisition criterion within 
the 25 day cut-off. A 2 (self-administration experience: none, 165 mg/kg) × 2 (eticlopride 
dose: 0.0, 0.3) ANOVA was conducted to compare locomotor challenge data following 
self-administration with locomotor challenge data from experiment 1. Rats pre-treated with 
MDMA (0.0 mg/kg) were omitted from these analysis since too few rats met the second 
acquisition criteria. 
For significant two-way interactions, simple main effect analyses were carried out 
to probe for differences using a Bonferroni corrected alpha level. Significant effects 
revealed by these tests were followed up with Bonferroni pairwise comparisons or Tukey 
post hoc tests. Degrees of freedom were adjusted (Greenhouse-Geisser) for tests of within-
subjects effects when the assumption of sphericity had been violated, as assessed by 
Mauchly’s test of sphericity. The level of significance for all tests was p < .05. 
Results 
Experiment 1: MDMA-induced behavioural sensitisation.  
Development of sensitisation. Figure 1 shows the total (top), centre (centre), and 
peripheral (bottom) locomotor activity produced by the various pre-treatment conditions 
during the five pre-treatment sessions. The left column displays the effect of eticlopride 
(0.0, 0.05, 0.3 mg/kg) on saline-produced locomotor activity. The centre column displays 
the effect of MDMA (0.0 or 10.0 mg/kg) following a saline injection on locomotor 
activity. The right column displays the effect of eticlopride (0.0, 0.05, 0.3 mg/kg) on 
MDMA-produced locomotor activity.   
To probe whether eticlopride (0.0, 0.05, 0.3 mg/kg) alone influenced basal (saline-
produced) locomotor activity (figure 1 - left column), these data were subjected to separate 
3 (eticlopride dose) × 5 (session) mixed measures ANOVAs on total, centre, and 
peripheral locomotor activity. The statistical values for these tests are displayed in 
appendix A: table A1. All three ANOVAs returned significant interactions. However, there 
were no significant simple main effects of eticlopride dose on any of the five sessions for 
total, centre, or peripheral locomotor activity indicating that eticlopride did not influence 
basal locomotor activity.  
To examine the effect of repeated MDMA (0.0 or 10.0 mg/kg) exposure on 
locomotor activity (figure 1 - centre column), separate 2 (MDMA dose) × 5 (session) 
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mixed measures ANOVAs were conducted on total, centre, and peripheral locomotor 
activity. The statistical values for these tests are displayed in table A2. The ANOVAs on 
total and peripheral locomotor activity failed to reveal significant interactions or main 
effects of session, but produced significant main effects of MDMA dose indicating that 
MDMA 10.0 mg/kg increased total and peripheral locomotor activity. The ANOVA on 
centre locomotor activity returned a significant interaction. Simple main effect analyses 
revealed that MDMA (10.0 mg/kg) increased centre locomotor activity on all five sessions. 
There was also a significant simple main effect of session on MDMA (10.0 mg/kg); simple 
comparisons revealed that MDMA-produced centre locomotor activity was greater on 
sessions 3 and 5 compared to session 2.  
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Figure 1. Average total (top), centre (centre), and peripheral (bottom) locomotor activity 
during the five days of pre-treatment for the various pre-treatment conditions in 
experiment 1. The left column displays the effect of eticlopride (0.0, 0.05, 0.3 mg/kg) on 
saline-produced locomotor activity. The centre column displays the effect of MDMA (0.0, 
10.0 mg/kg) following a saline injection. The right column displays the effect of 
eticlopride (0.0, 0.05, 0.3 mg/kg) on MDMA-(10.0 mg/kg) produced locomotor activity. 
Error bars represent standard error of the mean.  
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To probe whether eticlopride (0.0, 0.05, 0.3 mg/kg) influenced MDMA-produced 
locomotor activity (figure 1 - right column), separate 3 (eticlopride dose) × 5 (session) 
mixed measures ANOVAs were conducted on total, centre, and peripheral locomotor 
activity. The statistical values for these tests are displayed in table A3. The ANOVAs on 
total and peripheral locomotor activity failed to reveal significant interactions but produced 
significant main effects of eticlopride dose. Tukey post hoc analyses revealed that 
eticlopride 0.05 mg/kg and 0.3 mg/kg attenuated MDMA-produced total and peripheral 
locomotor activity. The ANOVA on centre locomotor activity returned a significant 
interaction. There were significant simple main effects of eticlopride dose on all sessions 
except session 2. Tukey post hoc analyses revealed MDMA-produced locomotor activity 
was attenuated by eticlopride 0.05 mg/kg on session 1 and by eticlopride 0.3 mg/kg on 
sessions 1, 3, 4, and 5.  
Centre versus peripheral activity. Figure 2 displays the percentage change in 
MDMA- (10.0 mg/kg) produced centre and peripheral locomotor activity relative to 
session one. A 2 (box zone) × 5 (session) repeated measures ANOVA produced a 
significant interaction (statistical values are displayed in table A4). Simple main effect 
analyses revealed that the percentage change in centre locomotor activity was lower than 
the percentage change in peripheral locomotor activity on session 2. There was also a 
simple main effect of session on the percentage change in centre locomotor activity; 
simple comparisons revealed that the percentage change in centre locomotor activity was 
lower on session 2 compared to sessions 3 and 5.  
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Figure 2. The average percentage change in centre and peripheral locomotor activity from 
baseline (session 1) during the five pre-treatment sessions for rats treated with MDMA 
(10.0 mg/kg) in experiment 1. Error bars represent standard error of the mean. * p < .01 
between centre and periphery.  
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Expression of locomotor sensitisation. Figure 3 shows the total, centre, and 
peripheral locomotor activity produced by MDMA (5 mg/kg) following two days of 
withdrawal from the various five-day pre-treatment regimens. Figure 3A displays total 
locomotor activity, which largely reflects peripheral activity. The statistical values for the 
following tests are displayed in table A5. A 3 (eticlopride dose) × 2 (MDMA dose) 
ANOVA on these data returned a significant interaction. Simple main effect analyses 
revealed that MDMA- (5 mg/kg) produced total locomotor activity was greater in rats pre-
treated with MDMA (10.0mg/kg) indicating a sensitised locomotor response. There was 
also a significant simple main effect of eticlopride on MDMA- (10.0 mg/kg) produced 
sensitisation; simple comparisons revealed that co-administration of eticlopride 0.05 
mg/kg and 0.3 mg/kg during pre-treatment blocked the sensitised locomotor response 
observed in MDMA pre-treated rats.  
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Figure 3. Average total (A), centre (B), and peripheral (C) locomotor activity produced by 
MDMA (5 mg/kg) following two days of withdrawal from pre-treatment with eticlopride 
(0.0, 0.05, 0.3 mg/kg) and MDMA (0.0, 10.0 mg/kg). Error bars represent standard error of 
the mean. * p < .05 compared to eticlopride (0.0 mg/kg) / MDMA (0.0 mg/kg) pre-
treatment. # p < .05 compared to eticlopride (0.0 mg/kg) / MDMA (10.0 mg/kg) pre-
treatment. 
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Figure 3B and figure 3C displays the centre and peripheral locomotor activity, 
respectively. Separate 3 (eticlopride dose) × 2 (MDMA dose) ANOVAs on these data 
returned significant interactions. Simple main effect analyses revealed sensitised centre 
and peripheral locomotor responses for rats pre-treated with MDMA. There were also 
simple main effects of eticlopride on MDMA- (10.0 mg/kg) produced sensitisation of 
centre and peripheral locomotor activity; simple comparisons revealed that co-
administration of both doses of eticlopride (0.05 and 0.3 mg/kg) during pre-treatment 
blocked the development of the sensitised peripheral response whereas only the high dose 
of eticlopride (0.3 mg/kg) blocked the sensitised centre response.  
Figure 4 displays total locomotor activity in the 30 min prior to the administration 
of MDMA (5 mg/kg). A 3 (eticlopride dose) × 2 (MDMA dose) ANOVA failed to reveal a 
significant interaction, main effect of eticlopride dose, or main effect of MDMA dose, 
indicating that basal locomotor activity did not significantly differ as a function of pre-
treatment.  
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Figure 4. Average locomotor activity during the 30 min prior to the MDMA challenge as a 
function of pre-treatment with eticlopride (0.0, 0.05, 0.3 mg/kg) and MDMA (0.0, 10.0 
mg/kg). Error bars represent standard error of the mean. 
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Experiment 2: Acquisition of MDMA self-administration 
Development of locomotor sensitisation. Locomotor activity data during pre-
treatment were largely similar between experiment one and two. Figure 5 shows the total 
(top), centre (centre), and peripheral (bottom) locomotor activity produced by the various 
pre-treatment conditions during the five pre-treatment sessions. The left column displays 
the effect of eticlopride (0.0 or 0.3 mg/kg) on saline-produced locomotor activity. The 
centre column displays the effect of MDMA (0.0 or 10.0 mg/kg) following a saline 
injection on locomotor activity. The right column displays the effect of eticlopride (0.0 or 
0.3 mg/kg) on MDMA-produced locomotor activity.  
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Figure 5. Average total (top), centre (centre), and peripheral (bottom) locomotor activity 
during the five days of pre-treatment for the various pre-treatment conditions in 
experiment 2. The left column displays the effect of eticlopride (0.0, 0.3 mg/kg) on saline 
produced locomotor activity. The centre column displays the effect of MDMA (0.0, 10.0 
mg/kg) following a saline injection. The right column displays the effect of eticlopride 
(0.0, 0.3 mg/kg) on MDMA (10.0 mg/kg) produced locomotor activity. Error bars 
represent standard error of the mean. 
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To probe whether eticlopride (0.0 or 0.3 mg.kg) alone influenced basal (saline-
produced) locomotor activity (figure 5 - left column), these data were subjected to separate 
2 (eticlopride dose) × 5 (session) mixed measures ANOVAs on total, centre, and 
peripheral locomotor activity. The statistical values of these tests are displayed in appendix 
B: table B1. The ANOVAs on total and peripheral locomotor activity failed to reveal 
significant interactions but produced significant main effects of eticlopride dose indicating 
that eticlopride 0.3 mg/kg attenuated basal total and peripheral locomotor activity. The 
ANOVA on centre locomotor activity produced a significant interaction. Simple main 
effect analyses revealed that eticlopride 0.3 mg/kg attenuated basal centre locomotor 
activity on session 3.  
To examine the effect of repeated MDMA (0.0 or 10.0 mg/kg) exposure on 
locomotor activity (figure 5 - centre column), separate 2 (MDMA dose) × 5 (session) 
mixed measures ANOVAs were conducted on total, centre, and peripheral locomotor 
activity. The statistical values of these tests are displayed in table B2. The ANOVAs on 
total and centre locomotor activity returned significant interactions. Simple main effects 
analyses revealed that MDMA 10.0 mg/kg increased total and centre locomotor activity on 
all five sessions. There were also significant simple main effects of session on MDMA 
(10.0 mg/kg); simple comparisons failed to find any differences between sessions for 
MDMA-produced total locomotor activity but revealed that MDMA-produced centre 
locomotor activity was greater on sessions 4 and 5 compared to session 1. The ANOVA on 
peripheral locomotor activity failed to reveal a significant interaction or main effect of 
session, but produced a significant main effect of MDMA dose indicating that MDMA 10 
mg/kg increased peripheral locomotor activity.  
To probe whether eticlopride (0.0 or 0.3 mg/kg) influenced MDMA-produced 
locomotor activity (figure 5 - right column), separate 2 (eticlopride dose) × 5 (session) 
mixed measures ANOVAs were conducted on total, centre, and peripheral locomotor 
activity. The statistical values of these tests are displayed in table B3. The ANOVAs on 
total and peripheral locomotor activity failed to reveal significant interactions but produced 
significant main effects of eticlopride dose indicating that eticlopride 0.3 mg/kg attenuated 
MDMA-produced total and peripheral locomotor activity. The ANOVA on centre 
locomotor activity returned a significant interaction. Simple main effect analyses revealed 
that eticlopride 0.3 mg/kg attenuated MDMA-produced centre locomotor activity on all 
five sessions.  
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Centre versus peripheral locomotor activity. Figure 6 displays the percentage 
change in MDMA- (10.0 mg/kg) produced centre and peripheral locomotor activity 
relative to session one. A 2 (box zone) × 5 (session) repeated measures ANOVA produced 
a significant interaction (the statistical values are displayed in table B4). Simple main 
effect analyses revealed that the percentage change in centre locomotor activity was 
greater than the percentage change in peripheral locomotor activity on sessions 4 and 5. 
There were also significant simple main effects of session on the percentage change in 
centre and peripheral locomotor activity; simple comparisons failed to find any differences 
between sessions for peripheral locomotor activity, but revealed that the percentage change 
in centre locomotor activity was greater on session 4 and 5 compared to session 1.  
Rearing activity. Figure 7 displays rearing activity produced by the various pre-
treatment conditions during the five treatment sessions. The left panel displays the effect 
of eticlopride (0.0 or 0.3 mg/kg) on basal (saline-produced) rearing activity. A 2 
(eticlopride dose) × 5 (session) mixed measures ANOVA failed to reveal a significant 
interaction, or main effect of eticlopride dose, indicating that basal rearing activity was not 
influenced by eticlopride (statistical values are displayed in table B5). The centre panel 
displays the effect of MDMA (0.0 or 10.0 mg/kg) following a saline injection on rearing 
activity. A 2 (MDMA dose) × 5 (session) mixed measures ANOVA produced a significant 
interaction (statistical values displayed in table B6). Simple main effect analyses revealed 
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Figure 6. The average percentage change in centre and peripheral locomotor activity from 
baseline (session 1) during the five pre-treatment sessions for rats treated with MDMA 
(10.0 mg/kg) in experiment 2. Error bars represent standard error of the mean. * p < .01 
between centre and periphery. # p < .025 compared to session 1. 
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that MDMA 10.0 mg/kg increased rearing activity on sessions 3, 4, and 5. There was also 
a significant simple main effect of session on MDMA 10.0 mg/kg; simple comparisons 
revealed that MDMA- (10.0 mg/kg) produced rearing was greater on sessions 3, 4, and 5, 
compared to session 1. The right panel displays the effect of eticlopride (0.0 or 0.3 mg/kg) 
on MDMA-produced rearing activity. A 2 (eticlopride dose) × 5 (session) mixed measures 
ANOVA produced a significant interaction (statistical values displayed in table B7). 
Simple main effect analyses revealed that eticlopride 0.3 mg/kg attenuated MDMA-
produced rearing activity on sessions 3, 4, and 5.  
Acquisition of self-administration. Figure 8 displays the average number of 
inactive and active lever responses over the first three days of self-administration and the 
final three days prior to meeting acquisition criteria (for the rats that did; n = 26). A 2 
(lever) × 2 (time) repeated measures ANOVA on these data produced a significant 
interaction, F(1, 25) = 70.85, p < .001, ηp2 = .739. Simple main effect analyses revealed a 
significant preference for the active lever on the last three days of self-administration, F(1, 
25) = 63.09, p < .001, ηp2 = .716, but not on the first three days (p = .189; level of 
significance accepted at p < .025). Simple main effects also revealed a significant increase 
in the number of active lever responses, F(1, 25) = 103.74, p < .001, ηp2 = .806, but found 
no change in the number of left lever responses (p = .849; level of significance accepted at 
p < .025). 
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Figure 7. Average rearing activity during the five days of pre-treatment for the various 
pre-treatment conditions in experiment 2. The left panel displays the effect of eticlopride 
(0.0, 0.3 mg/kg) on saline produced rearing activity. The centre panel displays the effect of 
MDMA (0.0, 10.0 mg/kg) following a saline injection. The right panel displays the effect 
of eticlopride (0.0, 0.3 mg/kg) on MDMA (10.0 mg/kg) produced rearing activity. Error 
bars represent standard error of the mean. 
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Figure 9 displays the cumulative percentage of rats that met the acquisition criteria 
for MDMA self-administration for the various pre-treatment groups. The top panel shows 
that 44.44% of saline pre-treated control animals met the acquisition criterion compared to 
100% of rats pre-treated with MDMA. A significant Log-rank, Kaplan-Meier analysis 
indicated that the likelihood to meet acquisition criteria was greater for subjects pre-treated 
with MDMA, χ2(1) = 10.29, p < .001.  
The centre panel shows that 77.8% of rats pre-treated with eticlopride + MDMA 
met acquisition criteria compared to 100% of MDMA only pre-treated rats. A Log-rank, 
Kaplan-Meier survival analysis failed to reveal a difference between these two pre-
treatment groups indicating that co-administration of eticlopride failed to block the 
facilitation of MDMA self-administration observed in MDMA pre-treated rats (p = .628).  
The bottom panel shows the 100% of rats pre-treated with eticlopride alone met 
acquisition criteria compared to 44.44% of saline pre-treated controls. A significant Log-
rank, Kaplan-Meier survival analysis indicated that the likelihood to meet acquisition 
criteria was greater for subjects pre-treated with eticlopride alone, χ2(1) = 8.66, p = .003.  
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Figure 8. Average number of responses made on the inactive and active levers over the 
first three days of self-administration and the final three days prior to meeting acquisition 
criteria for the rats that acquired (n = 26). Error bars represent standard error of the mean. 
* p < .025 compared to inactive lever on the last three days. # p < .025 compared to active 
lever on the first three days.  
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Figure 9. Cumulative percentage of rats that met acquisition criteria for MDMA self-
administration over the 25 daily sessions following two days of withdrawal from the 
various pre-treatment conditions. The first listing in each legend indicates the eticlopride 
pre-treatment (saline, 0.3 mg/kg) and the second listing indicates the MDMA pre-
treatment (saline, 10.0 mg/kg). Sample sizes are also indicated in each legend.  
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Expression of locomotor sensitisation. Figure 10 displays the effect of eticlopride 
pre-treatment and self-administration experience on total locomotor activity produced by 
MDMA (5 mg/kg) following two days of withdrawal for rats pre-treated with MDMA 10.0 
mg/kg. A 2 (eticlopride dose) × 2 (self-administration experience) ANOVA failed to 
reveal a significant interaction (p = .694) or a main effect of self-administration experience 
(p = .180) indicating that MDMA self-administration experience did not influence 
MDMA-produced locomotor activity. A main effect of eticlopride dose, F(1, 26) = 17.43, 
p < .001, ηp2 = .401, indicated that co-administration of eticlopride 0.3 mg/kg during pre-
treatment attenuated the subsequent locomotor activating effects of MDMA regardless of 
self-administration experience.  
Discussion 
The aims of the present research were twofold. The first experiment investigated 
the role of D2 receptors in the development of sensitised MDMA-produced horizontal and 
vertical (rearing) locomotor activity following repeated intermittent exposure. The second 
experiment determined whether repeated intermittent exposure to MDMA would also 
sensitise to the reinforcing effects of MDMA, as measured by the acquisition of self-
administration, and determined the role of D2 receptor mechanisms.  
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Figure 10. Average total locomotor activity produced by MDMA (5 mg/kg) for rats pre-
treated with eticlopride (0.0, 0.3 mg/kg) and MDMA (10.0 mg/kg) with or without self-
administration experience. Error bars represent standard error of the mean.  
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Experiment 1: MDMA-induced behavioural sensitisation  
It is generally accepted that sensitised central DAergic mechanisms play an 
important role in the development and expression of behavioural sensitisation (Kalivas & 
Stewart, 1991; Pierce & Kalivas, 1997; Vanderschuren & Kalivas, 2000). This appears 
equally true for MDMA since repeated MDMA exposure produced behavioural 
sensitisation that was accompanied by sensitised DAergic responses in the NAcc (Kalivas 
et al., 1998) and changes in accumbal c-Fos expression (Colussi-Mas & Schenk, 2008). 
Moreover, repeated MDMA exposure resulted in cross-sensitisation to other, more potent, 
DAergic drugs including amphetamine and cocaine (Bradbury et al., 2012; Kalivas et al., 
1998). Both D1- and D2-like receptor mechanisms have been implicated since cross-
sensitisation to D1 and D2 agonists was also produced (Bradbury et al., 2012). Little is 
known about the involvement of these receptors in the development of MDMA 
sensitisation, however. Because the D1 antagonist, SCH-23390, failed to block the 
development of MDMA sensitisation (Ramos et al., 2004), the purpose of the first 
experiment was to determine the role of D2 receptors in the development of MDMA 
sensitisation. 
Repeated intermittent exposure to MDMA sensitised rats to the subsequent 
locomotor activating effects of MDMA, a finding that we, and several other researchers 
have previously demonstrated (Ball, Budreau, & Rebec, 2006; Bradbury et al., 2012; 
Colussi-Mas & Schenk, 2008; Kalivas et al., 1998; Ramos et al., 2004; Spanos & 
Yamamoto, 1989). As was hypothesised, the development of this sensitised response was 
prevented by the co-administration of the D2 antagonist, eticlopride, during MDMA pre-
treatment. This suggests that activation of D2 receptors is critical to the development of 
MDMA sensitisation. D2 receptor antagonists have also been found to prevent the 
development of methamphetamine sensitisation (Hamamura et al., 1991; Kuribara & 
Uchihashi, 1993, 1994; Kuribara, 1995, 1996) but have yielded mixed result regarding 
amphetamine and cocaine sensitisation (see Vanderschuren & Kalivas, 2000).  
Because D2 receptors function as postsynaptic heteroreceptors and as presynaptic 
autoreceptors, the nature of their involvement in MDMA sensitisation is not entirely 
straightforward. Compared to postsynaptic D2 receptors, D2 autoreceptors have greater 
affinity for dopamine and D2 ligands but are less abundant (Castro & Strange, 1993; 
Malmberg, Jackson, Eriksson, & Mohell, 1993; Missale et al., 1998). As such, the same D2 
ligand can produce a biphasic effect, preferentially affecting D2 autoreceptors when 
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administered at lower concentrations and acting on the more abundant postsynaptic 
receptors when administered at higher concentrations (Beaulieu & Gainetdinov, 2011). For 
example, a low dose of the D2/3 agonist, quinpirole (0.03 mg/kg), decreased locomotor 
activity whereas higher doses (0.5 – 8.0 mg/kg) increased locomotor activity (Eilam & 
Szechtman, 1989). In the present study, relatively high doses of eticlopride were used that 
completely blocked MDMA-produced locomotor activity. This effect could only be due to 
antagonism of postsynaptic D2 receptors since selective antagonism of D2 autoreceptors 
would have been expected to produce the opposite effect (Bello et al., 2011; Cabib, 
Castellano, Cestari, Filibeck, & Puglisi-Allegra, 1991; Eilam & Szechtman, 1989).  
We have previously shown that repeated MDMA exposure also sensitised rats to 
the behavioural effects of relatively high doses of quinpirole (Bradbury et al., 2012), which 
suggests that that repeated MDMA exposure might lead to a sensitisation of postsynaptic 
D2 receptor mechanisms. Given that eticlopride prevented the development of MDMA 
sensitisation (present findings), this neuroadaptation may be a mechanism underlying the 
development and expression of MDMA sensitisation. Several studies have found evidence 
for sensitised postsynaptic D2 receptor mechanisms following repeated exposure to other 
drugs of abuse (De Vries, Schoffelmeer, Binnekade, & Vanderschuren, 1999; Ujike, 
Akiyama, & Otsuki, 1990; Vanderschuren, Schoffelmeer, Mulder, & De Vries, 1999). For 
example, rats exposed to a sensitising regimen of amphetamine were also sensitised to the 
behavioural effects of quinpirole and displayed an increased number of high affinity 
postsynaptic D2 binding sites four weeks later (Seeman, McCormick, & Kapur, 2007). 
Future research could determine whether a sensitising regimen of MDMA exposure 
similarly leads to an increase in postsynaptic D2 receptor binding sites and correlate this 
with sensitised behavioural responses.  
To ensure that the present findings were not an artefact of differences in basal 
locomotor activity between the various pre-treatment groups, locomotor activity was 
measured during the initial 30 min prior to the MDMA challenge on day 8. There were no 
significant differences between pre-treatment groups indicating this was not a contributing 
factor. The possibility of a conditioned locomotor response to the i.p. injection, while 
unlikely, cannot be discounted, however, because the locomotor response to a saline 
injection was not measured. Although previous studies using the same pre-treatment 
regimen and testing methods failed to find a difference in saline-produced locomotor 
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activity between MDMA and saline pre-treated rats (Bradbury et al., 2012; Colussi-Mas & 
Schenk, 2008). 
Centre versus peripheral activity. The pattern of hyperactivity produced by 
MDMA differs from that produced by other psychostimulants in that it is typically 
restricted to the periphery of a closed chamber (Bradbury et al., 2012; Gold et al., 1988; 
Ludwig et al., 2008; McCreary et al., 1999; Palenicek et al., 2005). In order to gain more 
insight into the effects of repeated MDMA exposure, the present study also measured 
centre and peripheral locomotor activity. Acute MDMA administration produced far 
greater increases (6 – 10 fold) in peripheral activity compared to centre activity. As has 
been previously documented (Bradbury et al., 2012; Colussi-Mas & Schenk, 2008; Ludwig 
et al., 2008; McCreary et al., 1999), this profile of hyperactivity changed with repeated 
exposure. Total locomotor activity increased, but the relative increase in centre activity 
(314%) was greater than the relative increase in peripheral activity (168%). This cannot be 
due to a ceiling effect whereby peripheral activity simply cannot increase any further since 
peripheral activity produced by the MDMA (5 mg/kg) challenge was, at most, ~50% of 
that produced by the higher dose of MDMA (10 mg/kg) used during pre-treatment. Rather, 
it has been suggested that this effect reflects sensitisation of the DAergic effects of 
MDMA, as the pattern of hyperactivity begins to more closely resemble that produced by 
amphetamine (Bradbury et al., 2012).  
The extent to which sensitised D2 receptor mechanisms contribute to this effect is 
unclear. In the present study, although the higher dose of eticlopride (0.3 mg/kg) blocked 
the sensitisation of both centre and peripheral activity, the lower dose (0.05 mg/kg) failed 
to block the sensitisation of centre activity but still completely blocked the sensitisation of 
peripheral activity. Further, eticlopride (0.05 mg/kg) only significantly attenuated MDMA-
produced centre activity during the first session of pre-treatment but consistently blocked 
MDMA-produced peripheral activity. It should be noted, though, that a floor effect may 
have occluded a significant attenuation of centre activity. Nevertheless, these findings 
allude to previous studies that have suggested D2 receptors play a more prominent role in 
peripheral locomotor activity (Eilam, Clements, & Szechtman, 1991; Eilam, Golani, & 
Szechtman, 1989; Risbrough et al., 2006). Much like MDMA, quinpirole-produced 
hyperactivity was primarily restricted to the periphery of the activity chamber (Eilam et al., 
1991, 1989). Further, a genetic deletion of D2, but not D1 or D3 receptors, specifically 
decreased the amount of peripheral activity produced by MDMA (Risbrough et al., 2006). 
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Based on these findings, sensitisation of D2 receptor mechanisms might explain the 
sensitisation of MDMA-produced peripheral activity but cannot explain the 
disproportionate sensitisation of centre activity. 
One potential explanation is that repeated MDMA exposure also sensitises D1 
receptor mechanisms. Much like amphetamine, D1 receptor agonists typically produce 
locomotor activity that is more generalised over the entire activity chamber (Eilam et al., 
1991; Meyer, Van Hartesveldt, & Potter, 1993; Salmi & Ahlenius, 2000). Administration 
of the D1 agonist, SKF-38393, dose-dependently increased the proportion of centre activity 
produced by quinpirole (Eilam et al., 1991), a change in the pattern of hyperactivity similar 
to that which occurs with repeated MDMA exposure. Thus, the disproportionate 
sensitisation of centre activity following repeated MDMA exposure might reflect 
sensitisation of D1 receptor mechanisms. Although SCH-23390 did not block the 
development of MDMA locomotor sensitisation, centre and peripheral activity was not 
specifically measured (Ramos et al., 2004). Given that centre activity represents a small 
proportion of total locomotor activity produced by MDMA, even when sensitised, if SCH-
23390 did block the development of centre activity sensitisation in this study it might not 
have significantly influenced total locomotor activity. To address this possibility, future 
research could investigate the effect of D1 antagonists on the development of sensitisation 
to MDMA-produced centre activity.  
Avoidance of the centre of a closed chamber has often been used as an index of 
anxiety (Crawley, 1985; Ennaceur, Michalikova, & Chazot, 2006; File, 2001). Thus, an 
increase in centre activity as a function of repeated MDMA exposure might alternatively 
reflect tolerance to the anxiogenic effects of MDMA. In support of this idea, more time 
was spent in the open arms of an elevated plus maze (Bull, Hutson, & Fone, 2004) and the 
latency to emerge from a hide box into an open field was decreased (Jones, Brennan, 
Colussi-Mas, & Schenk, 2010) following repeated MDMA exposure. These effects were 
attributed to 5-HTergic mechanisms since the dosing regimens used in these studies 
produced 5-HT depletion. The dosing regimen used in the present study, however, 
consisted of much lower doses of MDMA that did not produce 5-HT depletion (Bradbury 
et al., 2012). Changes in post-synaptic 5-HT receptor mechanisms or stimulated 5-HT 
release remain as possibilities, though, and could be measured following a similar regimen 
of repeated MDMA exposure in future research.  
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MDMA-produced locomotor activity data (total, centre and peripheral) during the 
five-days of pre-treatment were slightly different between experiment one and experiment 
two. Locomotor activity on day one, experiment one, was particularly high and therefore 
no changes in MDMA-produced locomotor activity were apparent over the five days of 
pre-treatment. In experiment two, however, locomotor activity on day one was relatively 
low and a gradual increase in MDMA-produced locomotor activity was observed during 
the five-day pre-treatment period, indicative of sensitisation. These inconsistencies might 
reflect differences in the handling of the rats between the two experiments (Gentsch, 
Lichtsteiner, Frischknecht, Feer, & Siegfried, 1988; Harkin, 2000; Pritchard, Van Kempen, 
& Zimmerberg, 2013). In experiment two, rats were handled daily prior to pre-treatment 
and had experience with injections due to the surgical procedure and post-operative care 
required for catheter implantation. In contrast, rats in experiment one were completely 
naive, with no handling or experience with injections. In order to determine whether this 
was the basis for the differences between experiments, additional studies could be 
conducted with comparable handling between groups.  
Rearing activity. Acute MDMA administration typically supresses rearing activity 
(Callaway et al., 1990; Fone et al., 2002; Kehne et al., 1996; Ludwig et al., 2008; 
Sadananda et al., 2012; M. R. Thompson et al., 2007). In experiment two of the present 
research, acute MDMA (10 mg/kg) administration did not significantly influence total 
rearing activity; however, time course analysis revealed that MDMA significantly 
increased rearing activity during the final 20 min of the session (data not shown). 
Consistent with this finding, Gold and colleagues found that although MDMA initially 
supressed rearing, the highest dose of MDMA (10 mg/kg) increased rearing 90 min after 
administration (Gold et al., 1988).  
During the five-day pre-treatment regimen, MDMA-produced rearing activity 
dramatically increased, indicative of sensitisation. This is consistent with findings from 
previous studies that have also found increased rearing activity following repeated MDMA 
exposure (Ludwig et al., 2008; Schenk & Bradbury, 2015). Evidence suggests that 
increased DAergic activity underlies rearing activity (Bubar et al., 2004; Hoffman & 
Beninger, 1985; Kalivas et al., 1984; Molloy & Waddington, 1985; Vazquez-DeRose et 
al., 2013). The increase in MDMA-produced rearing as a function of repeated exposure 
might, therefore, reflect the sensitisation of DAergic mechanisms. In support of this idea, 
acute administration of S(+)-MDMA, the more potent DA releasing isomer, typically 
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increases rearing activity whereas racemic ±MDMA, as mentioned previously, typically 
does not (Bubar et al., 2004; Callaway et al., 1990; Herin et al., 2005; Kehne et al., 1996; 
McCreary et al., 1999). Unfortunately, because rearing activity data were not available 
from experiment one, there was no specific test for the expression of rearing sensitisation. 
Therefore, the involvement of D2 receptors in the development of this sensitised response 
was not determined. Rearing activity produced by acute MDMA administration was 
completely blocked by eticlopride, however, which is consistent with previous findings 
(Bubar et al., 2004).  
The increase in rearing activity as a function of repeated MDMA exposure might 
alternatively reflect a decrease in behavioural competition between rearing activity and 5-
HT syndrome behaviours. In rats, acute MDMA administration produces components of 
the 5-HT syndrome including flat body posture, splayed hind limbs, forepaw treading, and 
head weaving (Spanos & Yamamoto, 1989). These behaviours, particularly flat body 
posture, are incompatible with rearing activity. Indeed, MDMA-produced flat body posture 
was inversely related to rearing activity; acute S(+)-MDMA administration increased flat 
body posture primarily during the beginning of the test session and increased rearing 
during the end of the session (Bubar et al., 2004). Tolerance to 5-HT syndrome behaviours 
occurs rapidly and has been reported following repeated MDMA exposure under 
conditions that produced decreases in tissue levels of 5-HT (Baumann, Clark, Franken, et 
al., 2008; Shankaran & Gudelsky, 1999). As mentioned previously, the dosing regimen 
used in the present study did not produce 5-HT depletion (Bradbury et al., 2012), although 
decreases in stimulated 5-HT release or other 5-HTergic mechanisms may contribute to the 
tolerance of these behaviours. If so, an inverse relationship between MDMA produced 5-
HT syndrome behaviours and rearing activity would be expected during a regimen of 
repeated MDMA exposure.  
Experiment 2: Acquisition of MDMA self-administration 
It has been suggested that DAergic neuroadaptations underlying behavioural 
sensitisation contributes to the formation of excessive drug-taking and drug-seeking 
behaviour (Robinson & Berridge, 1993). Support for this theory comes from several 
studies that have demonstrated that repeated exposure to drugs of abuse, under conditions 
that produced behavioural and DAergic sensitisation, facilitated the subsequent acquisition 
of self-administration and enhanced responding on progressive ratio schedules (for a 
review see Vezina, 2004). To the best of our knowledge, a similar experiment has not been 
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conducted using MDMA. We therefore determined the effect of a sensitising regimen of 
MDMA exposure on the subsequent acquisition of self-administration.  
Consistent with what has been found with other drugs of abuse (see Vezina, 2004), 
repeated exposure to MDMA under conditions that produced behavioural sensitisation also 
produced sensitisation to the reinforcing effects of MDMA, as evidenced by a facilitated 
acquisition of self-administration. As expected, rats pre-treated with MDMA were more 
likely to meet acquisition criteria compared to saline pre-treated controls, which displayed 
similar acquisition rates to what we have previously found using naive subjects (Schenk et 
al., 2012).  
Because sensitising regimens of MDMA exposure have been shown to enhance 
MDMA-produced NAcc DA release (Kalivas et al., 1998), and the reinforcing effects of 
MDMA have been attributed to DAergic mechanisms (Brennan et al., 2009; Daniela et al., 
2004), sensitised central DAergic mechanisms may underlie the facilitated acquisition of 
self-administration observed in the present study. In support of this idea, naive rats that 
met acquisition criteria for MDMA self-administration displayed enhanced MDMA-
produced striatal DA release (Colussi-Mas et al., 2010). Further, repeated MDMA 
exposure also facilitated the acquisition of cocaine self-administration (Fletcher et al., 
2001), an effect that was attributed to sensitised central DAergic mechanisms induced by 
repeated MDMA exposure (Fletcher et al., 2001; Morgan et al., 1997). If enhanced 
MDMA-produced DA release underlies sensitisation to the reinforcing effects of MDMA, 
future research could measure MDMA-produced synaptic DA using in vivo microdialysis 
following the same regimen of repeated MDMA exposure and relate it to the subsequent 
acquisition of self-administration.  
Eticlopride + MDMA pre-treatment. To determine the role of D2 receptors, the 
effect of eticlopride pre-treatment in combination with MDMA on sensitisation to the 
reinforcing effects of MDMA was also determined. Procedures that prevent the 
development of behavioural and DAegric sensitisation have been shown to also prevent 
the subsequent facilitation of drug taking (Vezina, 2004). Therefore, since eticlopride 
blocked the development of MDMA sensitisation (experiment 1), it was hypothesised that 
eticlopride would also block the facilitated acquisition of MDMA self-administration 
observed in MDMA pre-treated rats. Although a lesser percentage of rats met acquisition 
criteria, the likelihood that a subject would meet acquisition criteria by day 25 was not 
significantly decreased by eticlopride + MDMA pre-treatment. These findings suggest that 
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while D2 receptor mechanisms may play some role, other mechanisms contributed to the 
development of sensitisation to the reinforcing effects of MDMA.  
One such mechanism might involve changes in 5-HT neurotransmission as a result 
of repeated MDMA exposure. Increased 5-HT is generally inhibitory the reinforcing 
effects of drugs abuse (e.g. McGregor et al., 1993; Roberts et al., 1999; Wee & 
Woolverton, 2006; Wee et al., 2005). This is particularly evident for MDMA; the 
acquisition of MDMA self-administration was greatly facilitated by 5-7 DHT lesions or a 
genetic mutation of the 5-HT transporter (Bradbury et al., 2013; Oakly et al., 2013). 
Further, MDMA-produced increases in NAcc 5-HT were negatively correlated with the 
propensity to self-administer MDMA (Bradbury et al., 2013). Tolerance to the 5-HTergic 
effects of MDMA, therefore, would be expected to facilitate the acquisition of self-
administration. As previously mentioned, repeated exposure to high doses of MDMA 
produces deficits in 5-HTergic neurotransmission (see Baumann et al., 2007; Green et al., 
2003; Ricaurte et al., 2000). Even though the dosing regimen used in the present study did 
not produce 5-HT depletion (Bradbury et al., 2012), changes in other indices of 5-HTergic 
neurotransmission following this particular dosing regimen have not been determined and 
might be a contributing factor. A decrease in stimulated 5-HT release, for example, has 
been demonstrated following repeated self-administered MDMA (Reveron et al., 2010) 
and would be expected to facilitate the acquisition of MDMA self-administration. Changes 
in postsynaptic 5-HT receptor mechanisms may also have been a contributing factor since 
a downregulation of 5-HT1a receptors induced by pre-treatment with the 5-HT1a/1b agonist, 
RU-24969, facilitated the acquisition of self-administration (Aronsen, Bukholt, & Schenk, 
2016).  
Therefore, as we have previously suggested (Schenk, 2011), both the sensitisation 
of DAergic mechanisms (including D2 receptor mechanisms) and tolerance to the 5-HT 
releasing effects of MDMA might be contributing factors to the acquisition of reliable 
MDMA self-administration. Because we cannot determine that 5-HTergic 
neuroadaptations did not occur in the present study, the relative contribution of DAergic 
sensitisation and 5-HTergic tolerance remains to be elucidated. Future research could 
measure changes 5-HT receptor mechanisms or stimulated 5-HT release following a 
similar sensitising regimen of MDMA exposure. Alternatively, the effect of a sensitising 
regimen of more selective DAergic agonists, such as amphetamine or apomorphine, on the 
subsequent acquisition of MDMA self-administration could be determined.  
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Eticlopride pre-treatment. Interestingly, control rats pre-treated with eticlopride 
alone were also sensitised to the reinforcing effects of MDMA; 100% of these rats met 
acquisition criteria suggesting that D2 receptor mechanisms do indeed influence the 
acquisition of MDMA self-administration. Several studies have found that repeated 
administration of D2 antagonists results in an upregulation of these receptors (Braun, 
Laruelle, & Mouradian, 1997; Muller & Seeman, 1977; Tegner, 1977). For example, four 
days after receiving 21 days of daily eticlopride treatment (0.5 mg/kg), rats displayed an 
increased density of D2 binding sites (LaHoste & Marshall, 1991). Thus, in the present 
study, repeated eticlopride treatment may have induced a homeostatic upregulation of 
post-synaptic D2 receptors that facilitated the acquisition of MDMA self-administration.   
If such an upregulation of postsynaptic D2 receptors was evident two days 
following eticlopride pre-treatment, then a sensitised locomotor response to MDMA would 
also have been expected in experiment 1. Indeed, a post hoc one-way ANOVA revealed 
that eticlopride pre-treatment resulted in small increases in MDMA-produced locomotor 
activity that were approaching significance (p = .051; figure 3). Interestingly, these 
increases were only evident for peripheral locomotor activity, supporting previous 
suggestions that D2 receptors play a more prominent role in peripheral activity (Eilam et 
al., 1991, 1989; Risbrough et al., 2006). Similar findings have been found by previous 
studies. For example, subchronic blockade of D2 receptors in the VTA sensitised the 
locomotor activating effects of amphetamine (Tanabe, Suto, Creekmore, Steinmiller, & 
Vezina, 2004).  
In another study, intermediate doses of the D2 antagonist, sulpiride, attenuated- 
whereas high doses potentiated the development of methamphetamine sensitisation 
(Kuribara, 1996). Because of the longer half-life of sulpiride, the authors suggested that 
blockade of D2 receptors by the high dose of sulpiride persisted long after the effects of 
methamphetamine had worn off, which resulted in the upregulation of D2 receptors. In the 
present study, the opposite may have occurred for rats pre-treated with eticlopride + 
MDMA. Because the half-life of MDMA is much longer than eticlopride (R. L. Fitzgerald, 
Blanke, & Poklis, 1990; Norman, Tabet, Norman, & Tsibulsky, 2011), and because 
eticlopride was administered 30 min prior to MDMA, D2 receptor activation by MDMA 
may have persisted after the effects of eticlopride had worn off. Although this activation 
was evidently not enough to induce sensitisation, this may have prevented the upregulation 
of D2 receptors for rats that received eticlopride + MDMA. This would explain why an 
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additive effect of eticlopride + MDMA treatment was not observed in experiment one or 
two.  
Behavioural sensitisation. In order to examine the effect of self-administration 
experience on MDMA-induced sensitisation, the locomotor activating effect of MDMA 
was tested after a total of 165 mg/kg MDMA had been self-administered and compared to 
rats with no self-administration experience (experiment 1). Because too few saline pre-
treated controls met this second self-administration criterion, these comparisons were only 
made for rats pre-treated with MDMA (10 mg/kg) alone or in combination with 
eticlopride. 
It might have been expected that the additional MDMA exposure during self-
administration would have potentiated the sensitised response produced by MDMA pre-
treatment. Whereas for the rats pre-treated with eticlopride + MDMA (which were not 
sensitised to MDMA), it might have been expected that the additional exposure to MDMA 
without eticlopride treatment would have resulted in the development of a sensitised 
response. Locomotor responses to MDMA (5 mg/kg) did not differ between rats with or 
without self-administration experience, however, regardless of pre-treatment. Previous 
studies have shown that repeated MDMA exposure in a different environmental context 
fails to induce MDMA sensitisation (Ball et al., 2006; Ball, Klein, Plocinski, & Slack, 
2011). Because the additional exposure to MDMA was received in the context of self-
administration, this may not have influenced MDMA-produced locomotor activity in the 
locomotor testing chambers.  
Conclusions 
In experiment one, the role of D2 receptors in the development of sensitised 
MDMA-produced horizontal and vertical (rearing) locomotor activity following repeated 
intermittent exposure was determined. Repeated intermittent MDMA exposure sensitised 
rats to the locomotor activating effects of MDMA. Sensitisation of locomotor activity was 
proportionately greater in the centre than in the periphery of the activity chamber. Rearing 
activity also appeared to become sensitised with repeated MDMA exposure. The 
development of these sensitised behavioural responses was prevented by the co-
administration of eticlopride during MDMA pre-treatment indicating a critical role of D2 
receptors. It is suggested that repeated MDMA exposure results in the sensitisation of 
postsynaptic D2 receptors, which enhanced the locomotor activating effects of MDMA. 
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In experiment two, the effect of a sensitising regimen of MDMA exposure on the 
subsequent acquisition of MDMA self-administration was determined. As expected, pre-
treatment with MDMA sensitised the reinforcing effects of MDMA, evidenced by a 
facilitated acquisition of self-administration. Because the DAergic mechanisms underlying 
sensitisation to the locomotor activating and reinforcing effects of drugs of abuse are 
thought to be similar (Vezina, 2004), the contribution of D2 receptor mechanisms was also 
investigated. Eticlopride failed to completely block the facilitated acquisition of MDMA 
self-administration observed in MDMA pre-treated rats. This suggests that while D2 
receptor mechanisms may play some role, other mechanisms, such as tolerance to the 5-
HT release effects of MDMA, may contribute to the development of sensitisation to the 
reinforcing effects of MDMA. Finally, MDMA self-administration did not influence 
MDMA-produced locomotor activity, regardless of pre-treatment, emphasising the 
importance of environmental context in sensitisation research.   
These findings add to the growing body of literature implicating DAergic 
neuroadaptations in the development of sensitisation to drugs of abuse. It has been 
suggested that these neuroadaptations underlie the development of compulsive drug-taking 
and drug-seeking behaviour (Robinson & Berridge, 1993). A better understanding of how 
these neuroadaptations influence behaviour might, therefore, aid in the development of 
treatments that reverse these neuroadaptations, reducing the compulsive drug-taking and 
drug-seeking behaviour characteristic of addiction.  
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Experiment 1: statistical results. 
 
Table A1. 
3 (eticlopride dose: 0.0, 0.05, 0.3) × 5 (session: 1-5) mixed measures ANOVA  
Basal total locomotor activity 
Interaction: Etic dose × session F(8, 92) = 2.78, p = .009, ηp2 = .194 
Simple main 
effect: 
Etic dose on session 11 p = .099 
Etic dose on session 21 p = .057 
Etic dose on session 31 p = .060 
Etic dose on session 41 p = .106 
Etic dose on session 51 p = .415 
Basal centre locomotor activity 
Interaction: Etic dose × session F(8, 92) = 3.47, p = .002, ηp2 = .232 
Simple main 
effect: 
Etic dose on session 11 p = .436 
Etic dose on session 21 p = .297 
Etic dose on session 31 p = .154 
Etic dose on session 41 p = .091 
Etic dose on session 51 p = .071 
Basal peripheral locomotor activity 
Interaction: Etic dose × session F(8, 92) = 2.20, p = .035, ηp2 = .160 
Simple main 
effect: 
Etic dose on session 11 p = .061 
Etic dose on session 21 p = .052 
Etic dose on session 31 p = .060 
Etic dose on session 41 p = .181 
Etic dose on session 51 p = .744 
1 Level of significance accepted at p < .01.  
 
  




2 (MDMA dose: 0.0, 10.0) × 5 (session: 1-5) mixed measures ANOVA  
Total locomotor activity 
Interaction: MDMA dose × session p = .205 
Main effect: MDMA dose F(1, 19) = 149.80, p < .001, ηp2 = .887 
 Session p = .205 
Centre locomotor activity 




MDMA dose on session 11 F(1, 19) = 20.88, p < .001, ηp2 = .524 
MDMA dose on session 21 F(1, 19) = 18.32, p < .001, ηp2 = .491 
MDMA dose on session 31 F(1, 19) = 44.60, p < .001, ηp2 = .701 
MDMA dose on session 41 F(1, 19) = 28.95, p < .001, ηp2 = .604 
MDMA dose on session 51 F(1, 19) = 90.19, p < .001, ηp2 = .826 
Session on MDMA 10.0 F(4, 40) = 5.82, p = .001, ηp2 = .368 
Simple 
comparisons2: 
Session 2 vs 3 p = .026 
Session 2 vs 5 p < .001 
Peripheral locomotor activity 
Interaction: MDMA dose × session p = .476 
Main effect: MDMA dose F(1, 19) = 117.92, p < .001, ηp2 = .861 
 Session p = .355 
1 Level of significance accepted at p < .01.  
2 All other comparisons were not significant. 
 
  




3 (eticlopride dose: 0.0, 0.05, 0.3) × 5 (session: 1-5) mixed measures ANOVA 
MDMA-produced total locomotor activity 
Interaction: Etic dose × session p = .200 
Main effect: Etic dose F(2, 23) = 56.29, p < .001, ηp2 = .830 
 Session p = .112 
Tukey HSD: Etic 0.0 vs 0.05 p < .001 
 Etic 0.0 vs 0.03 p < .001 
 Etic 0.05 vs 0.3 p = .677 
MDMA-produced centre locomotor activity 




Etic dose on session 11 F(2, 23) = 9.91, p  = .001, ηp2 = .463 
Etic dose on session 21 p = .610 
Etic dose on session 31 F(2, 23) = 11.10,  p < .001, ηp2 = .491 
Etic dose on session 41 F(2, 23) = 6.23, p  = .007, ηp2 = .351 
Etic dose on session 51 F(2, 23) = 12.82, p  < .001, ηp2 = .368 
Tukey HSD 
(session 1): 
Etic 0.0 vs 0.05 p = .013 
Etic 0.0 vs 0.03 p = .001 
Etic 0.05 vs 0.3 p = .680 
Tukey HSD 
(session 3): 
Etic 0.0 vs 0.05 p = .164 
Etic 0.0 vs 0.03 p < .001 
Etic 0.05 vs 0.3 p = .054 
Tukey HSD 
(session 4): 
Etic 0.0 vs 0.05 p = .073 
Etic 0.0 vs 0.03 p = .007 
Etic 0.05 vs 0.3 p = .667 
Tukey HSD 
(session 5): 
Etic 0.0 vs 0.05 p = .141 
Etic 0.0 vs 0.03 p < .001 
Etic 0.05 vs 0.3 p = .033 
MDMA-produced peripheral locomotor activity 
Interaction: Etic dose × session p = .377 
Main effect: Etic dose F(2, 23) = 48.39, p < .001, ηp2 = .808 
 Session p = .093 
Tukey HSD: Etic 0.0 vs 0.05 p < .001 
 Etic 0.0 vs 0.03 p < .001 
 Etic 0.05 vs 0.3 p = .892 
1 Level of significance accepted at p < .01.  
 
  




2 (box zone: centre, periphery) × 5 (session: 1-5) repeated measures ANOVA 
Percent change in MDMA-produced total locomotor activity 
Interaction: Box zone × session F(4, 40) = 5.24, p = .002, ηp2 = .344 
Simple main 
effect: 
Box zone on session 11 p = .966 
Box zone on session 21 F(1, 10) = 17.96, p = .002, ηp2 = .642 
Box zone on session 31 p = .400 
Box zone on session 41 p = .605 
Box zone on session 51 p = .076 
Session on centre2 F(4, 40) = 5.84, p = .001, ηp2 = .369 




Session 2 vs 3 p = .026 
Session 2 vs 5 p < .001 
1 Level of significance accepted at p < .01. 
2 Level of significance accepted at p < .025. 





3 (eticlopride dose: 0.0, 0.05, 0.3) × 2 (MDMA dose: 0.0, 10.0) ANOVA 
Total locomotor activity 
Interaction: Etic dose × MDMA dose F(2, 44) = 10.17, p < .001, ηp2 = .316 
Simple main 
effect: 
MDMA dose on etic 0.0 F(1, 44) = 28.19, p < .001, ηp2 = .391 
Etic dose on MDMA 10.0 F(2, 44) = 8.84,  p = .001, ηp2 = .287 
Simple 
comparisons: 
Etic 0.0 vs 0.05 p = .022 
Etic 0.0 vs 0.3 p = .001 
Etic 0.05 vs 0.3 p = .999 
Centre locomotor activity 
Interaction: Etic dose × MDMA dose F(2, 44) = 4.37, p = .019, ηp2 = .166 
Simple main 
effect: 
MDMA dose on etic 0.0 F(1, 44) = 35.28, p < .001, ηp2 = .226 
Etic dose on MDMA 10.0 F(2, 44) = 8.16,  p = .001, ηp2 = .271 
Simple 
comparisons: 
Etic 0.0 vs 0.05 p = .442 
Etic 0.0 vs 0.3 p = .001 
Etic 0.05 vs 0.3 p = .089 
Peripheral locomotor activity 
Interaction: Etic dose × MDMA dose F(2, 44) = 8.57, p = .001, ηp2 = .280 
Simple main 
effect: 
MDMA dose on etic 0.0 F(1, 44) = 16.42, p < .001, ηp2 = .272 
Etic dose on MDMA 10.0 F(2, 44) =6.14,  p = .004, ηp2 = .218 
Simple 
comparisons: 
Etic 0.0 vs 0.05 p = .034 
Etic 0.0 vs 0.3 p = .008 
Etic 0.05 vs 0.3 p = .999 
Basal locomotor activity 
Interaction: Etic dose × MDMA dose p = .056 
Main effect: Etic dose p = .188 
MDMA dose p = .465 
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Appendix B  
Experiment 2: statistical results. 
 
Table B1. 
2 (eticlopride dose: 0.0, 0.3) × 5 (session: 1-5) mixed measures ANOVA  
Basal total locomotor activity 
Interaction: Etic dose × session p = .050 
Main effect: Etic dose F(1, 22) = 16.55, p = .001, ηp2 = .429 
Session p = .202 
Basal centre locomotor activity 




Etic dose on session 11 p = .090 
Etic dose on session 21 p = .026 
Etic dose on session 31 F(1, 22) = 11.12, p = .003, ηp2 = .336 
Etic dose on session 41 p = .224 
Etic dose on session 51 p = .083 
Basal peripheral locomotor activity 
Interaction: Etic dose × session p = .175 
Main effect: Etic dose F(1, 21) = 15.57, p = .001, ηp2 = .414 
Session p = .358 
1 Level of significance accepted at p < .01.  
 
  




2 (MDMA dose: 0.0, 10.0) × 5 (session: 1-5) mixed measures ANOVA  
Total locomotor activity 




MDMA dose on session 11 F(1, 22) = 99.55, p < .001, ηp2 = .819 
MDMA dose on session 21 F(1, 22) = 79.79, p < .001, ηp2 = .784 
MDMA dose on session 31 F(1, 22) = 64.99, p < .001, ηp2 = .747 
MDMA dose on session 41 F(1, 22) = 128.20, p < .001, ηp2 = .854 
MDMA dose on session 51 F(1, 22) = 102.88, p < .001, ηp2 = .824 
 Session on MDMA 10.0 F(4, 44) = 3.18, p = .022, ηp2 = .224 
Simple 
comparisons 
No significant differences   
Centre locomotor activity 




MDMA dose on session 11 F(1, 22) = 42.72, p < .001, ηp2 = .660 
MDMA dose on session 21 F(1, 22) = 16.52, p = .001, ηp2 = .429 
MDMA dose on session 31 F(1, 22) = 22.94, p < .001, ηp2 = .510 
MDMA dose on session 41 F(1, 22) = 40.96, p < .001, ηp2 = .651 
MDMA dose on session 51 F(1, 22) = 89.57, p < .001, ηp2 = .803 
Session on MDMA 10.0 F(4, 44) = 16.60, p < .001, ηp2 = .605 
Simple 
comparisons2: 
Session 1 vs 4 p = .005 
Session 1 vs 5 p < .001 
 Session 2 vs 4 p = .037 
 Session 2 vs 5 p = .025 
 Session 3 vs 4 p = .009 
 Session 3 vs 5 p = .003 
Peripheral locomotor activity 
Interaction: MDMA dose × session p = .201 
Main effect: MDMA dose F(1, 22) = 364.21, p < .001, ηp2 = .943 
 Session p = .214 
1 Level of significance accepted at p < .01. 
2 All other comparisons were not significant. 
 
  




2 (eticlopride dose: 0.0, 0.3) × 5 (session: 1-5) mixed measures ANOVA 
MDMA-produced total locomotor activity 
Interaction: Etic dose × session p = .065 
Main effect: Etic dose F(1, 21) = 272.95, p < .001, ηp2 = .929 
 Session F(2.72, 57.17) = 3.10, p = .038, ηp2 = 
.128 
MDMA-produced centre locomotor activity 




Etic dose on session 11 F(1, 21) = 32.95, p < .001, ηp2 = .611 
Etic dose on session 21 F(1, 21) = 9.69, p = .005, ηp2 = .316 
Etic dose on session 31 F(1, 21) = 15.88, p = .001, ηp2 = .431 
Etic dose on session 41 F(1, 21) = 28.60, p < .001, ηp2 = .577 
Etic dose on session 51 F(1, 21) = 75.09, p < .001, ηp2 = .781 
MDMA-produced peripheral locomotor activity 
Interaction: Etic dose × session p = .274 
Main effect: Etic dose F(1, 22) = 271.20, p < .001, ηp2 = .928 
 Session p = .202 








2 (box zone: centre, periphery) × 5 (session: 1-5) repeated measures ANOVA 
Percent change in MDMA-produced total locomotor activity 
Interaction: Box zone × session F(4, 44) = 16.21, p < .001, ηp2 = .596 
Simple main 
effect: 
Box zone on session 11 p = .994 
Box zone on session 21 p = .430 
Box zone on session 31 p = .122 
Box zone on session 41 F(1,11) = 17.97, p = .001, ηp2 = .620 
Box zone on session 51 F(1,11) = 44.50, p < .001, ηp2 = .802 
Session on centre2 F(4,44) = 17.67, p < .001, ηp2 = .616 




Session 1 vs 4 p < .001 
Session 1 vs 5 p < .001 
Session 2 vs 4 p < .030 
Session 2 vs 5 p < .029 
Session 3 vs 4 p < .002 




No significant differences  
1 Level of significance accepted at p < .01.  
2 Level of significance accepted at p < .025.  




2 (eticlopride dose: 0.0, 0.3) × 5 (session: 1-5) mixed measures ANOVA 
Basal rearing activity 
Interaction: Etic dose × session p = .708 
Main effect: Etic dose p =.055 








2 (MDMA dose: 0.0, 10.0) × 5 (session: 1-5) mixed measures ANOVA 
Rearing activity 
Interaction: Etic dose × session p = .708 
Simple main 
effect: 
Etic dose p =.055 
Session p = .758 
 MDMA dose on session 11 p = .098 
 MDMA dose on session 21 p = .054 
 MDMA dose on session 31 F(1, 22) = 15.18, p = .001, ηp2 = .408 
 MDMA dose on session 41 F(1, 22) = 32.44 p < .001, ηp2 = .596 
 MDMA dose on session 51 F(1, 22) = 22.72, p < .001, ηp2 = .606 




Session 1 vs 3 p = .001 
Session 1 vs 4 p < .001 
Session 1 vs 5 p < .001 
Session 2 vs 3 p = .004 
Session 2 vs 4 p < .001 
Session 2 vs 5 p = .002 
1 Level of significance accepted at p < .01.  






2 (eticlopride dose: 0.0, 0.3) × 5 (session: 1-5) mixed measures ANOVA 
MDMA-produced rearing activity  




Etic dose on session 11 p = .034 
Etic dose on session 21 p = .032 
Etic dose on session 31 F(1, 21) =16.38, p = .001, ηp2 = .438 
Etic dose on session 41 F(1, 21) = 31.32, p < .001, ηp2 = .599 
Etic dose on session 51 F(1, 21) = 35.57, p < .001, ηp2 = .629 
1 Level of significance accepted at p < .01.  
